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I. INTRODUCTION 
With the 2020 presidential election looming, healthcare 
reform is emerging as a major campaign issue. Numerous ideas, 
from creation of a national single payer system, to major 
overhauls of Medicare/Medicaid, to significantly revising 
coverage requirements mandated under the Affordable Care Act, 
are in play. While the scope and details of health reform 
proposals are highly variable, the underlying issues, which any 
significant reform initiative will face, are universal and constant. 
Undoubtedly, the biggest challenge all health reform proposals 
confront concerns crafting innovative and meaningful approaches 
to addressing the pervasive fiscal pressures faced by government 
programs. There is a long history of attempts to “bend the cost 
curve,” but this complex task remains elusive in the face of 
evolving demand and supply side pressures.1 One large point of 
consensus in the complex arena of cost containment policy is a 
 
 * Bernard Beazley Chair in Health Law & Policy, Loyola University Chicago School 
of Law. Special thanks to my Loyola colleague, Professor Shawn R. Mathis, for her helpful 
review and comments. 
 1 See Ehsan U. Syed, Will We Ever Bend the Cost Curve in Healthcare?, AM. HEALTH 
& DRUG BENEFITS (July 2019), http://www.ahdbonline.com/issues/2019/june-july-2019-vol-
12-no-4/2789-will-we-ever-bend-the-cost-curve-in-healthcare [http://perma.cc/ABN5-LY8Z]. 
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general agreement that there must be a direct assault on chronic 
health diseases, such as obesity, heart disease, and cancer. It is 
estimated by the Centers for Disease Control and Prevention 
(“CDC”) that six in ten adults suffer from at least one chronic 
disease, and that this category of illnesses is a major driver of our 
nation’s $3.3 trillion in healthcare costs.2 No comprehensive 
health reform can succeed unless it promotes strategies to 
effectively mitigate the burden of chronic diseases. 
Few chronic diseases have a greater impact on health costs 
than substance use disorders. While opioid addiction may be the 
most current and visible form of substance use disorders, it is 
part of a broader, ongoing epidemic that includes the abuse of 
licit and illicit drugs, as well as alcohol.3 One of our nation’s 
oldest substance use disorders is cigarette smoking—a behavior 
that is driven by nicotine, the highly addictive chemical found in 
tobacco.4 Cigarette consumption is widely recognized as leading 
to multiple, serious health problems.5 It is an ongoing public 
health epidemic and has been the focus of regulators and health 
organizations since the release of the U.S. Surgeon General’s 
Report on Smoking in 1964.6 In the many years in which a war 
against tobacco has been waged by public and private actors, 
great progress has been made in reducing the number of smokers 
in the U.S. from 43% in 1965 to less than 16% currently.7 But 
even in the face of progress, cigarette smoking remains our most 
preventable cause of death—higher than AIDS, alcoholism, 
 
 2 Chronic Diseases in America, NAT’L CTR. FOR CHRONIC DISEASE PREVENTION & HEALTH 
PROMOTION, http://www.cdc.gov/chronicdisease/pdf/infographics/chronic-disease-H.pdf 
[http://perma.cc/SKU5-WKLF] (last updated Sept. 12, 2019). It has also been estimated 
that four in ten adults suffer from two or more chronic health conditions. Id. 
 3 See Trends & Statistics, NAT’L INST. ON DRUG ABUSE, http://www.drugabuse.gov/ 
related-topics/trends-statistics [http:perma.cc/2Y3F-TZJQ] (last updated Apr. 2017) 
(estimating the health costs of substance use disorders to be as high as $250 billion 
annually). For further details on the opioid epidemic, see What is the U.S. Opioid 
Epidemic?, U.S. DEP’T OF HEALTH & HUMAN SERVS., http://www.hhs.gov/opioids/about-
the-epidemic/index.html [http://perma.cc/4MGT-YLUL] (last updated Sept. 4, 2019). 
 4 See Is nicotine addictive?, NAT’L INST. ON DRUG ABUSE, http://www.drugabuse.gov/ 
publications/research-reports/tobacco-nicotine-e-cigarettes/nicotine-addictive 
[http://perma.cc/5VQU-B74A] (last updated Oct. 2019) (discussing the addictive 
properties of nicotine).  
 5 See Kayla Ruble, Read the Surgeon General’s 1964 Report on Smoking and Health, 
PBS (Jan. 12, 2014, 2:00 PM), http://www.pbs.org/newshour/health/first-surgeon-general-
report-on-smokings-health-effects-marks-50-year-anniversary [http://perma.cc/8P85-ELVR].  
 6 See id. 
 7 See Smoking is down, but almost 38 Million American adults still smoke, CTRS. 
FOR DISEASE CONTROL & PREVENTION (Jan. 18, 2018), http://www.cdc.gov/media/releases/ 
2018/p0118-smoking-rates-declining.html [http://perma.cc/YEG8-YE8E]; Smoking in 
America: Why more Americans are kicking the habit, AM. HEART ASS’N (Aug. 30, 2018), 
http://www.heart.org/en/news/2018/08/29/smoking-in-america-why-more-americans-are-
kicking-the-habit [http://perma.cc/EYR8-EB9E]. 
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murder, suicide, and use of illegal drugs combined.8 According to 
the CDC, smoking-related illnesses cost more than $300 billion a 
year in direct medical expenses and lost productivity; it is an 
addiction that accounts for 8.7% of healthcare spending, of which 
60% is paid for by public sources.9 The burdens of smoking on our 
health delivery system continue to be profound and any success 
we may have in containing healthcare costs will be realized only 
by continuation of the decades-long struggle to mitigate the 
tobacco epidemic.  
The so-called war against tobacco has a long, detailed, and 
well-documented history that spans the second half of the 
twentieth century and continues to the present.10 This robust 
history of regulation reveals an assortment of abatement 
strategies that pit public health actors against individual 
smokers, powerful manufacturers, retailers, and agricultural 
interests. Central to this history is the role of law as a basic tool 
to implement an array of public policies and interventions on 
both domestic and international levels.11 The ubiquitous presence 
of law in the struggle against tobacco products has been divided 
into two distinct periods: the first being a long period in which 
the focus of regulation rests on tobacco as an agricultural 
product, and the second characterized by public protection, in 
which preventing and reducing the health impacts of 
consumption is dominant.12 These two periods—private market 
regulation and public health oversight—are not sequential, but 
coexist as major focal points of activity.13  
For decades, the regulation of tobacco as a private product has 
focused on farming policies, product taxation, and various 
attempts to promote market competition through antitrust law.14 
 
 8 See U.S. DEP’T HEALTH & HUMAN SERVS., THE HEALTH CONSEQUENCES OF 
SMOKING—50 YEARS OF PROGRESS: A REPORT OF THE SURGEON GENERAL 678–79 (2014); 
Smoking and Death, CTRS. FOR DISEASE CONTROL & PREVENTION (Jan. 17, 2018), 
http://www.cdc.gov/tobacco/data_statistics/fact_sheets/health_effects/effects_cig_smoking/
index.htm [http://perma.cc/D7HP-UNVD]. 
 9 Fast facts, CTRS. FOR DISEASE CONTROL & PREVENTION, http://www.cdc.gov/tobacco/ 
data_statistics/fact_sheets/fast_facts/index.htm [http://perma.cc/N5Q8-GZDF] (last updated 
Feb. 6, 2019); Xin Xu et al., Annual Healthcare Spending Attributable to Cigarette Smoking, 
48 AM. J. PREVENTATIVE MED. 326, 331 (2015). 
 10 See Helene M. Cole & Michael C. Fiore, The War Against Tobacco: 50 Years and 
Counting, 311 JAMA 131–32 (2014) (providing a summary of the turn of public health 
policy against tobacco).  
 11 For an overview of the long history of tobacco regulation, see NAT’L COMM’N ON 
MARIHUANA & DRUG ABUSE, History of Tobacco Regulation, 1 APPENDIX: MARIHUANA: A 
SIGNAL OF MISUNDERSTANDING 514 (1972), http://hdl.handle.net/2027/umn.31951d 
03118410v [http://perma.cc/J8ND-T8KP]. 
 12 See id. 
 13 See GIDEON DORON, THE SMOKING PARADOX 5 (Michael Connolly et al. eds., 1979). 
 14 See id. at 5–12. 
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The focus on public health regulation can be traced to a growing 
awareness of the correlations between smoking and disease that 
has gone from anecdotal speculation to scientific certainty.15 
Public good regulations are characterized by a host of mandates, 
from labeling and advertisement requirements, to age restrictions, 
to product content oversight.16 The legal system’s impact on 
smoking has arisen from a mélange of statutory directives at all 
levels of government, in addition to litigation—particularly the 
1998 Master Settlement Agreement that promoted widespread 
adoption of restrictions on tobacco products.17  
A central feature in any consideration of tobacco control 
concerns the response of the regulated. The growing, 
manufacturing, and selling of tobacco products is a large, 
sophisticated, and profitable industry, and even in the face of 
long-term scrutiny, this sector has been able to adjust to 
regulations by adopting strategies of aggression and 
accommodation as needed. Paradoxically, the tobacco companies 
that adamantly denied that smoking caused health problems 
during the twentieth century, now caution against this behavior, 
positing smoking as a matter of adult choice and advocating that 
smokers switch to their newest product line, e-cigarettes.18  
This Article offers commentary on one legal strategy that has 
been used in the long-term struggle to control tobacco: the use of 
package warning labels. First introduced in 1965 in the Federal 
Cigarette Labeling and Advertising Act (“FCLAA,” also referred 
to as the Cigarette Act), a label-warning mandate has since 
become a basic feature of tobacco regulation.19 It is the second 
piece of federal legislation enacted during the 91st Congress, the 
Public Health Cigarette Smoking Act (“PHCSA”),20 that modified 
cigarette label warning requirements and which will be the 
springboard for analysis in this Article. This piece will explore 
the evolution and changes in the law concerning federal cigarette 
package warnings, tracing legislative iterations in the area from 
a basic textual requirement originating in the 1960s,21 to the 
 
 15 See id. at 12–15. 
 16 See id. at 14–19. 
 17 See Pete Levin, The ABCs of the Tobacco Master Settlement Agreement, 
2 NAAG, Nov. 6, 2007, at 1–2, http://www.naag.org/assets/files/pdf/gazette/1.2.Gazette.pdf 
[http://perma.cc/U49K-7PEL].  
 18 See E-Cigarettes: Facts, stats and regulations, TRUTH INITIATIVE (July 19, 2018), 
http://truthinitiative.org/research-resources/emerging-tobacco-products/e-cigarettes-facts-
stats-and-regulations [http:perma.cc/TR9S-SSEC].  
 19 Federal Cigarette Labeling and Advertising Act, Pub. L. No. 89–92, 79 Stat. 282 
(codified in 15 U.S.C. §§ 1331–1336, 1338–1340 (2012)).  
 20 Public Health Cigarette Smoking Act of 1969, Pub. L. No. 91–222, 84 Stat. 87 
(codified in 15 U.S.C. § 1340 (2012)). 
 21 See id. 
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much more complex requirement to add graphic health warnings 
enacted in 2009.22 Undoubtedly the issue of tobacco warning 
labels is only one of many threads in the larger context of 
cigarette regulation, but it is one which provides a helpful 
window into the exploration of policies to address the public 
health epidemic of smoking. The adoption and changes to 
warning labels reflect the historic environments in which such 
anti-smoking policies were developed and demonstrate an 
ongoing tension between regulators and industry. While tobacco 
control is a pillar of public health, it is not an exact science, as 
best practices, such as warnings, are difficult to measure and 
uncertain in the face of evolving smoking practices, like the use of 
e-cigarettes. As in other areas of smoking policy, political and legal 
impediments abound in the warning arena, compromising 
government capabilities to find an endgame to this persistent 
epidemic. The goal of this Article is to identify lessons that can be 
garnered from a review of the law concerning cigarette-package 
warnings to both improve that process and, more broadly, confront 
the ongoing challenges smoking poses to our healthcare system.  
II. BACKGROUND 
The rise and fall of cigarettes is a story ingrained in the 
twentieth century. The combination of mass production and 
skillful marketing moved the cigarette from relative obscurity in 
1900 to a central place in American life by the 1930s.23 While 
tobacco use exploded both domestically and internationally, it 
was cigarette consumption that dominated and became the 
epicenter of this behavior.24 Cigarettes were marketed as highly 
desirable products, and ads depicting smoking as tasteful, 
healthy, and refreshing were seen for years in all forms of 
advertising media.25 The advertisements were diverse in 
character, with various brands arguing that their products were 
 
 22 See Family Smoking Prevention and Tobacco Control Act, Pub. L. No. 111–31, 123 
Stat. 1776 (codified in 21 U.S.C. §§ 387, 387a–387u, 387a–1, 387f–1 (2012)). 
 23 See ALLAN M. BRANDT, THE CIGARETTE CENTURY: THE RISE, FALL AND DEADLY 
PERSISTENCE OF THE PRODUCT THAT DEFINED AMERICA 2–3 (2007). 
 24 See id. at 97. 
 25 See Cigarette Advertising Themes, STAN. UNIV., http://tobacco.stanford.edu/ 
tobacco_main/main.php [http://perma.cc/E8QZ-N36L] (last visited Sept. 18, 2019). 
Cigarette advertisements are iconic symbols of American life, often depicting well-known 
personalities of the day touting the attractiveness of smoking as healthful and refreshing. 
See id. A prime example of characteristic advertising can be found on the pages of 
America’s most popular weekly magazine, Life Magazine; the back-cover page of the 
magazine was often devoted to full page, artful tobacco advertisements that are reflective 
of the culture surrounding cigarettes. See Stuart Elliot, Once a Mainstay of Magazines, 
Cigarette Makers Drop Print Ads, N.Y. TIMES (Nov. 29, 2007), http://www.nytimes.com/ 
2007/11/29/business/media/29adco.html [http://perma.cc/8YR8-UGTG].  
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less irritating to the smoker’s throat, thereby cloaking 
themselves in the imprimatur of medical endorsements.26  
At the time cigarette smoking was reaching its zenith, seeds 
of concern about the health implications had been widely sown. 
In the early part of the twentieth century, criticism of cigarettes 
on moral grounds was as common as concerns over health, which 
somewhat paralleled reactions against alcohol use.27 The public 
health case against cigarettes evolved over a considerable period 
of time as the epidemiological proof linking smoking with cancer 
became more convincing and spilled over from scientific 
literature into every day parlance.28 Tobacco companies 
vigorously fought back, orchestrating a massive public relations 
effort to empathize with health concerns, while simultaneously 
calling into question the validity of the science linking cigarette 
consumption to disease.29  
In the 1940s and 1950s, the tobacco industry challenged the 
validity of anti-smoking studies, and even financed its own 
research that called into question claims that the product was a 
gateway to serious health problems.30 In addition to adopting a 
posture of aggressive denials over health claims, tobacco 
manufacturers began to introduce filtered cigarettes to reduce 
harmful tar and nicotine content, which paradoxically should not 
have been necessary had these products not been potentially 
harmful to begin with.31 Another popular strategy used to market 
cigarettes was for manufacturers to make claims about the low 
levels of tar and nicotine in a given brand, arguing the result was 
less throat irritation, and, by implication, constituted a healthier 
product.32 As more scientific research about the ills of smoking 
unfolded, the industry shifted from a rejection of causation to 
arguments that there was simply inadequate proof about the 
dangers of smoking to reach a definitive conclusion.33 Through 
much of the twentieth century, cigarettes were largely 
 
 26 See Martha M. Gardner & Allan M. Brandt, “The Doctors’ Choice Is America’s 
Choice”: The Physician in U.S. Cigarette Advertisements, 1930–1953, 96 AM. J. PUBLIC 
HEALTH 222, 223–24 (2006). 
 27 Id. at 222; see U.S. DEP’T HEALTH & HUMAN SERVS., THE HEALTH CONSEQUENCES 
OF SMOKING—50 YEARS OF PROGRESS: A REPORT OF THE SURGEON GENERAL 19 (2014). 
 28 See Gardner & Brandt, supra note 26, at 222–23. 
 29 See id. at 223. 
 30 See Allan M. Brandt, Inventing Conflicts of Interest: A History of Tobacco Industry 
Tactics, 102 AM. J. PUBLIC HEALTH 63, 63–64 (2012).  
 31 See Gardner & Brandt, supra note 26, at 229–30.  
 32 Joel B. Cohen, Smokers’ Knowledge and Understanding of Advertised Tar 
Numbers: Health Policy Implications, 86 AM. J. PUBLIC HEALTH 18, 19 (1996).  
 33 See STANTON A. GLANTZ ET AL., THE CIGARETTE PAPERS 25 (1996) (“After millions 
of dollars and over twenty years of research, the question about smoking and health is 
still open.”). 
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unregulated, with the exception of Federal Trade Commission 
(“FTC”) oversight, which had control over unfair trade 
practices.34 The FTC did issue a number of cease and desist 
orders involving various advertising claims made in particular 
cigarette brand ad campaigns, but it lacked the capacity to 
contain an industry that was able to nimbly adjust advertising 
strategies to circumvent regulatory challenges.35 Following 
Congressional tobacco hearings in 1957 that highlighted the 
deceptive nature of tobacco advertising, a movement to attach 
warning labels to cigarette packaging developed.36 
Eventually the weight of science pressured the government 
to take action to evaluate the accumulating evidence linking 
smoking and illness, and a government commission was created 
in 1962 under the auspices of the U.S. Surgeon General to look 
into the matter.37 In early January of 1964, the U.S. Surgeon 
General’s Advisory Committee on Smoking and Health issued 
what has become a seminal report in the history of tobacco 
control.38 It was a catalyst in the design of multidisciplinary 
health studies, which also sparked subsequent Surgeon General 
smoking evaluations.39 
The Surgeon General’s Report, based on review of over 7,000 
articles on smoking and health, concluded “that cigarette 
smoking is—[a] cause of lung and laryngeal cancers in men[,] a 
probable cause of lung cancer in women[,]” as well as a “cause of 
 
 34 See Federal Trade Commission Act, 15 U.S.C. § 49 (Supp. IV 1970) (using the 
subpoena power to investigate instances of unfair methods of competition).  
 35 See Statement of Basis and Purpose for the Cigarette Advertising and Labeling 
Trade Regulation Rule, 29 Fed. Reg. 8325 (July 2, 1964). On September 15, 1955, the FTC 
issued cigarette-advertising guides. 1960 FTC ANN. REP. at 82. Among other things, they 
prohibit representations in cigarette advertising or labeling which refer to the presence or 
absence of any physical effects from cigarette smoking or which make any 
unsubstantiated claims respecting nicotine, tar or any other components of cigarette 
smoke, or in any other respects contain misleading implications concerning the health 
consequences or the advertised brand. See id. at 83. In 1960, the Commission obtained the 
agreement of the leading cigarette manufacturers to discontinue the misleading and 
unsubstantiated representations of tar and nicotine content which had characterized the 
so-called tar derby. See id. The FTC was limited in its regulatory authority over tobacco 
as the additional authority granted to the FTC in 1938 through the Food, Drug, and 
Cosmetic Act did not include tobacco; it took time for the Commission to ban tar and 
nicotine content, as unsubstantiated health claims, lacking in proof or uniform testing. 
Federal Food, Drug, and Cosmetic Act, ch. 675, 52 Stat. 1040 (Supp. IV 1930) (codified as 
amended in scattered sections of 21 U.S.C.). 
 36 See BRANDT, supra note 23, at 246. 
 37 See id. at 219.  
 38 U.S. DEP’T HEALTH, EDUC., & WELFARE, PUB. HEALTH SERV. PUB. NO. 1103, 
SMOKING AND HEALTH: REPORT OF THE ADVISORY COMMITTEE TO THE SURGEON GENERAL 
OF THE PUBLIC HEALTH SERVICE (1964). 
 39 Id. 
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chronic bronchitis.”40 The report did not end scientific issues 
concerning cigarette smoking, but did resolve any uncertainty 
about whether there was a link between tobacco and illness, and 
as such, created an avenue for government to more forcefully 
address the smoking problem directly. 
The Surgeon General’s Report emerged in a period where 
smoking rates were high and, as noted, product regulation over 
cigarette content and manufacturing processes was largely 
non-existent. With cigarettes established as a type of disease 
vector by the Surgeon General, the initial focus of federal 
regulatory activity was centered on addressing the myths 
spawned by aggressive and misleading ad claims.41 The challenge 
of moving the report from a scientific analysis to remedial action 
fell to the FTC, which quickly unveiled a new set of regulations 
that mandated warnings about the dangers of smoking under the 
Commission’s authority to safeguard against unfair and 
deceptive trade practices.42 The FTC issued a proposed rule, 
which, in part, specified that one of two prescribed warnings be 
prominently displayed in all advertisements and on every 
cigarette pack, box, or container, as well as in advertisements.43 
This FTC rulemaking sparked a national debate on cigarette 
regulation that shifted the issue from a question of science to one 
of politics, and raised questions about the scope of regulatory 
authority in this arena. While the FTC proposal to add powerful 
warnings concerning the dangers of smoking garnered strong 
support from most public health groups, surprisingly the 
American Medical Association (“AMA”) did not endorse tobacco 
warning labels, but instead, for political reasons, called for 
increasing research into the public health implications of 
smoking, rather than adoption of warnings that the AMA felt 
would likely be ignored.44 
 
 40 History of the Surgeon General’s Reports on Smoking and Health, CTR. FOR 
DISEASE CONTROL & PREVENTION, http://www.cdc.gov/tobacco/data_statistics/sgr/history/ 
index.htm [http://perma.cc/2M8P-49UD] (last updated Dec. 18, 2018). The Report 
concluded that the death rates for male smokers from lung cancer were 1,000% higher 
than male nonsmokers. BRANDT, supra note 23, at 224. 
 41 See Advertising and Labeling of Cigarettes, 29 Fed. Reg. 530, 530–32 (Jan. 22, 1964). 
 42 See id. 
 43 M. JOYCELYN ELDERS, PREVENTING TOBACCO USE AMONG YOUNG PEOPLE: A 
REPORT OF THE SURGEON GENERAL 257 (1994) (stating, caution: (a) “The Surgeon 
General's Advisory Committee on Smoking and Health has found that cigarette smoking 
contributes substantially to mortality from certain specific diseases and to the overall 
death rate”; or (b) “Cigarette smoking is dangerous to health. It may cause death from 
cancer and other diseases.").  
 44 It has been suggested that the AMA was caught up in its fights against Medicare 
and Medicaid legislation and did not want to alienate tobacco state members of Congress. 
BRANDT, supra note 23, at 249. In a JAMA editorial, the Executive Director of the AMA 
argued that tobacco had such large and multi-faceted implications that Congress, and not 
Do Not Delete 5/22/20 8:51 AM 
2020] Tobacco Product Warnings in the Mist of Vaping 61 
While the science linking smoking to disease was advanced 
by the Surgeon General’s Report, the tobacco war quickly took on 
a strong public policy cast as the tobacco lobby, shifted its efforts 
to the political arena, and waged its battles in Congress. Tobacco 
had powerful allies in Congress, led by members from tobacco 
growing states who had close ties to President Lyndon 
B. Johnson.45 While the FTC was pushing for greater regulatory 
control over cigarettes, the tobacco industry went on the offensive 
by threatening litigation to block the Commission’s expansion of 
tobacco regulations and proposing its own legislative fixes, which 
were reflected in Senate Bill 559.46 Striking testimony in 
Congressional tobacco hearings was provided by some of the 
nation’s leading cancer specialists who argued that the statistical 
link between smoking and health was not powerful enough to 
discount other multiple causes that might underlie lung cancer.47 
At this point, the tobacco lobby recognized that the 
pendulum of science and public opinion about smoking had 
shifted, thereby making warnings inevitable. So, rather than 
fight this development, it supported a very diluted 
warning: “Caution: Cigarette Smoking May Be Hazardous to 
Your Health.”48 Ironically, while the smoking lobby continued to 
question the science around this behavior as uncertain, it 
supported a warning label as a mechanism to notify consumers 
about the dangers of smoking, and as a strategy to mitigate 
potential liability, thus creating an assumption of risk on the 
part of the smoker.49 In addition, the industry sought to restrict 
FTC regulation and supported placing future labeling and 
advertising regulations in Congressional control, preempting 
state and local activities in this area.50 On another front, a 
Tobacco Industry Code of Advertising was adopted in 1964.51 The 
Code was a form of self-regulation, directed at prohibiting ads 
geared toward youth smoking, ensuring accuracy in health 
 
a regulatory agency, should control labeling and advertising. F.J.L. Blasingame, Full Text 
of AMA Letter of Testimony to FTC, in 188 JAMA 31, 31 (1964). In addition, the Tobacco 
Research Industry Committee in 1964 (renamed the Council for Tobacco Research) had 
pledged $10 million to the AMA Education and Research Foundation to conduct research 
into the possible association between smoking and health. See 21 CONG. Q. SERV., Health 
Warning Required on Cigarette Packs, in XXI CONG. Q. ALMANAC 344 (Henrietta Poynter 
et al. eds., 1965). 
 45 See CONG. Q. SERV., supra note 44, at 344.  
 46 See id. at 344–45. 
 47 See id. at 348. 
 48 See id. at 345. 
 49 See BRANDT, supra note 23, at 254.  
 50 Id. 
 51 John W. Richards, Jr. et al., The Tobacco Industry’s Code of Advertising in the 
United States: Myth and Reality, 5 TOBACCO CONTROL 295, 295 (1996). 
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claims, and creating an administrative mechanism to vet 
advertisements based on the first two objectives noted.52 
In July of 1965, the FLCAA was signed into law by President 
Lyndon B. Johnson, despite the White House failing to endorse 
this bill and a lack of unanimity in the Executive branch about 
how tobacco control should be developed.53 Opposition from key 
members of Congress, who feared any federal legislation that 
might adversely impact the economics of tobacco growing and 
product taxation, certainly played a critical role in what was 
contained in this legislation.54 The tobacco lobby heavily 
influenced this federal law, and the conditions noted above 
(warning labels, preemptions, regulatory agency limitations) 
were incorporated into this statute, making it a very pro-industry 
enactment.55 Nonetheless, even if the law was highly 
compromised, The Cigarette Act remains significant, as it was 
the first of several pieces of federal legislation enacted to regulate 
tobacco products, and represents a foundation on which 
subsequent tobacco legislation rests. The Cigarette Act required 
a conspicuous package-warning label that codified the explicit 
language to be included, by January 1966, on all domestic and 
imported cigarette packaging.56 The warning mandate was a step 
towards the legal recognition of the dangers of smoking that had 
been endorsed by the U.S. Surgeon General as a matter of public 
education, even if it was much less stringent than what health 
advocates had hoped for.57 The Cigarette Act placed a four-year 
moratorium on any additional federal, state, or local agency 
regulation of advertisements, as well as restricted federal 
agencies from requiring language in warning labels beyond what 
was specified in the statute.58 While the FTC still retained its 
general powers to regulate cigarettes under its authority over 
unfair and deceptive trade practices, the FCLAA moratorium 
shifted power to Congress and struck a blow against agency 
autonomy in this field.59 The law required that the Department 
of Health, Education, and Welfare (“DHEW”) submit regular 
reports to Congress about the health consequences of smoking, 
 
 52 Id.  
 53 Federal Cigarette Labeling and Advertising Act, 15 U.S.C. §§ 1331–1341 (1966). 
 54 See CONG. Q. SERV., supra note 44, at 346.  
 55 See id. at 345–46. 
 56 Id. at 345.  
 57 See NAT’L COMM’N ON MARIHUANA & DRUG ABUSE, supra note 11, at 523.  
 58 Id. The law prohibited the FTC from requiring that the warning be placed in tobacco 
advertisements. For a discussion of the preemption question that was later dealt with by the 
U.S. Court, see CONG. RESEARCH SERV., R40639, THE FEDERAL CIGARETTE LABELING AND 
ADVERTISING ACT AND PREEMPTION REVISITED: AN ANALYSIS OF THE SUPREME COURT CASE 
ALTRIA GROUP, INC. V. GOOD AND CURRENT LEGISLATION 14–16 (2009). 
 59 See NAT’L COMM’N ON MARIHUANA & DRUG ABUSE, supra note 11, at 523.  
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and that the FTC submit reports on the effectiveness of labeling 
and the impacts of advertising on smoking.60 
III. THE PUBLIC HEALTH CIGARETTE SMOKING ACT AND THE 
91ST CONGRESS 
Through ongoing research in the 1960s, it became clearer 
that smoking causes multiple health problems and that this 
awareness was taking root in the public consciousness.61 On the 
other hand, tobacco sales were at their zenith and smoking rates 
even increased in 1966 after mandated package-warning labels 
were legislated in the FCLAA.62 The economic power of the 
tobacco industry and the success of cigarette advertising made 
smoking a difficult target for public health advocates.63 But there 
were broader societal health concerns beyond smoking—such as 
increasing cancer rates generally and growing fears over 
illnesses caused by environmental toxins—that affected the 
regulatory climate of the 1960s.64 In addition, it was during this 
time that the country experienced the growth of the consumer 
movement, in which an emphasis on safety, information, choice, 
and redress emerged as legal levers to empower individuals in 
the face of large corporate interests.65 These broad societal forces 
came together during the Nixon administration and it was in this 
period that the 91st Congress was confronted with deciding what 
should be included in a new tobacco law in light of the sunset of 
key portions of FCLAA—particularly those concerning agency 
authority and package warning requirements. 
The concerns about the ill effects of cigarettes did not 
subside after the passage of the FCLAA, but continued into the 
late 1960s, driven to a considerable extent on the political side by 
the Nixon administration’s U.S. Surgeon General, Jesse 
Steinfeld.66 Dr. Steinfeld, a cancer researcher from the National 
Cancer Institute, was a very strong anti-smoking advocate who 
used his position as Surgeon General as a bully pulpit to attack 
the tobacco industry; he argued that tobacco companies were 
 
 60 See id. 
 61 See id. 
 62 See id. 
 63 See id. 
 64 See Robert Lichter, Stop the Fearmongering Over Cancer, FORBES (June 1, 2010, 11:24 
AM), http://www.forbes.com/2010/06/01/cancer-hysteria-health-media-opinions-columnists-robert-
lichter.html#163564cc3348 [http://perma.cc/M99L-24UH]. 
 65 See Richard L. Worsnop, Directions of the Consumer Movement, in CQ 
RESEARCHER 3–4 (1972).  
 66 See Alison Snyder, Jesse Steinfeld, 384 LANCET 1258, 1258 (Oct. 4, 2014), 
http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(14)61760-8/fulltext 
[http://perma.cc/6FD7-BUHA]. 
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responsible for millions of related deaths.67 Particularly 
noteworthy was Steinfeld’s campaign that cautioned women 
about the dangers of smoking while pregnant or near children, 
and his pioneering work in raising concern about the dangers of 
secondhand smoke that underpinned a call to ban smoking in 
public places.68 Steinfeld’s vigorous advocacy proved controversial 
and unpopular with key political operatives in the Nixon 
administration who feared backlash from the tobacco industry 
and political fallout in states that were heavily dependent on this 
crop as a mainstay of their agricultural economies.69 It was also 
argued that the Surgeon General was overly concerned with the 
health impacts of smoking, at the expense of taking action to 
combat other health hazards.70 
In the period following the FCLAA, a number of important 
smoking-related developments occurred beyond the vigorous 
anti-smoking advocacy of the Surgeon General. In 1966, a 
request was made to television station WCBS to broadcast 
anti-smoking announcements under the equal time provisions of 
the fairness doctrine.71 During this era, cigarettes were the 
leading product advertised on television, accounting for 8% of 
advertising time.72 The argument was made that the law 
governing broadcast media required that airtime also be allotted 
to public health advocates to present information about the 
health risks of smoking to counter the false representations made 
in cigarette commercials.73 The Federal Communications 
Commission (“FCC”) supported the use of the fairness doctrine to 
counteract cigarette ads as a matter of public interest.74 Later 
use of this doctrine was upheld in the federal courts where the 
argument that it violated First Amendment commercial speech 
protections was rejected.75 While “equal time” was not required 
for anti-tobacco ads, broadcasters were required to devote a 
“significant amount of time” to free messages that educated the 
 
 67 Id. 
 68 Id. 
 69 “Any attacks on tobacco are counter-productive in Kentucky, North Carolina and 
Virginia, where tobacco-growing and manufacturing are vital to the economy. The same is 
true to a lesser, but still significant, extent in Tennessee, Georgia, South Carolina, Florida 
and Maryland.” Memorandum for the Att’y Gen. from Lee R. Nunn, Comm. for the 
Re-Election of the President (Jan. 18, 1972). 
 70 See id. at Attachment C. 
 71 NAT’L COMM’N ON MARIHUANA & DRUG ABUSE, supra note 11, at 524.  
 72 SUSAN WAGNER, CIGARETTE COUNTRY: TOBACCO IN AMERICAN HISTORY & POLITICS 
166 (1971). 
 73 See Banzhaf v. FCC, 405 F.2d 1082, 1086 (D.C. Cir. 1968). 
 74 See id. at 1087. 
 75 See id. at 1100–01. 
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public about the hazards of smoking, and as such, frequent 
anti-tobacco spot ads began to populate the broadcast airwaves.76 
Under the dictates of the FCLAA, the FTC was temporarily 
prevented from implementing any requirement that tar and 
nicotine content be listed on cigarette packages.77 Still, the FTC, 
after many years of rejecting industry claims concerning 
cigarette content, reached a private agreement with tobacco 
manufacturers in 1966 to allow tar and nicotine content to be 
advertised.78 The Commission had convened a panel of scientists 
to explore the tar and nicotine issue.79 This panel concluded that 
there was sufficient evidence to support the claim that cigarette 
smoke that contained lower amounts of these two substances was 
less harmful and that recommendations should be made to the 
Surgeon General to support reduction of these harmful chemicals 
in cigarette smoke.80 Cigarette manufacturers were not required 
to include tar and nicotine content in advertisements, but could 
choose to do so without facing a regulatory penalty.81 The FTC 
required that advertised ingredients be based on accepted smoke 
testing procedures, even endorsing a particular testing method, 
and creating its own laboratory to conduct smoke tests.82  
In 1967, the FTC released a report on cigarette labeling and 
advertising, required under FCLAA.83 This report, based on 
survey data collected from public health professionals and 
consumers, concluded there was no evidence that the current 
label warning required in 1965 had any effect on cigarette 
consumption.84 In fact, in the first two months after the warning 
appeared, product sales actually increased.85 Survey respondents 
overwhelmingly reported that they felt that the current warning 
label language was insufficient to inform the public of the 
general hazards of smoking, particularly in the face of massive 
 
 76 Id. at 1086–87. 
 77 NAT’L COMM’N ON MARIHUANA & DRUG ABUSE, supra note 11, at 523. 
 78 See Vanessa K. Burrows, CONG. RESEARCH SERV., RS22944, FEDERAL TRADE 
COMMISSION GUIDANCE REGARDING TAR AND NICOTINE YIELDS IN CIGARETTES (2008). 
For FTC guidance on tar and nicotine, see FTC, FTC to Begin Cigarette Testing, 
NEWS SUMMARY (Aug. 18, 1967), http://hdl.handle.net/2027/uiug.30112104343899 
[http://perma.cc/P8YT-34QR]. 
 79 Cigarette Controls: A Sick Joke So Far, 33 CONSUMER REPS. 97, 102 (1968). 
 80 Id. The tar and nicotine measures were also seen as a helpful tool to dispel the 
belief that filtered cigarettes were effective in reducing harmful chemicals in smoke, as 
filtered cigarettes seen as healthier dominated the cigarette market. Id. 
 81 See Burrows, supra note 78. 
 82 See Jeffrey Wigand, What is the FTC Method of Cigarette Analysis?, 
http://jeffreywigand.com/FTCmethod.pdf [http://perma.cc/X9MK-YTPE] (last visited Feb. 27, 
2020); Burrows, supra note 78. 
 83 FTC ANN. REP. at 18–19, 78–79 (1967). 
 84 Cigarette Controls: A Sick Joke So Far, supra note 79, at 98. 
 85 Id. 
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industry advertising.86 The Commission expressed concern about 
the impacts of advertising on teenagers who appeared to be a 
prime target of television cigarette promotions.87 Tobacco ads 
depicted smoking as a relatively safe and fashionable behavior, 
never pointing out the addictive nature of the product.88 The FTC 
noted that the industry did not appear to be following its own 
self-regulatory guidelines—particularly evident in its promotion 
of filtered cigarettes and its failure to mention the increasing 
evidence of the growing health hazards linked to smoking.89 The 
Commission report recommended that package warnings be more 
stringent, using language that reads, “Cigarette Smoking Is 
Dangerous to Health and May Cause Death From Cancer and 
Other Diseases,” and that such warning be expanded from 
packages to all product advertising, and mandate specific tar and 
nicotine content information.90 In addition, the FTC called for 
appropriations of funds to support anti-smoking programs, 
especially for children, as well as support for the development of 
a “safer” cigarette.91 
The broad health concerns over cancer and environmental 
pollution became legislative drivers of the 91st Congress and, 
within this context, the ongoing battle over how tobacco was to 
be regulated unfolded. Within the cigarette-smoking arena, the 
aggressive posture of the Surgeon General and the FTC, 
together with the use of the fairness doctrine mandated by the 
FCC, drove government’s executive branch smoking activism. A 
Congressional showdown on tobacco in 1969 was sparked by the 
sunset provision in the FCLAA concerning warning language and 
advertisement regulation.92 Numerous tobacco bills were 
introduced in the U.S. House of Representatives in 1969 that 
posited several primary approaches for ongoing regulation, 
including a stronger warning label, the inclusion of tar and 
nicotine levels on packaging and advertisements, prohibition of 
broadcast cigarette ads, as well as extension of provisions of the 
1965 FCLAA.93 During the time period the 91st Congress was 
deliberating new cigarette legislation, the FCC began 
rule-making processes to ban the broadcast of cigarette ads on 
 
 86 See id. 
 87 Id. 
 88 See id. at 98, 100. 
 89 See id. at 100. 
 90 Id. 
 91 See id. 
 92 See S. REP. NO. 91-566, at 1–2 (1969), as reprinted in 1970 U.S.C.C.A.N. 2652, 
2652–53. 
 93 Edward Klebe, CONG. RESEARCH SERV., 79-219EPW, ACTIONS OF THE CONGRESS 
AND THE FEDERAL GOVERNMENT ON SMOKING AND HEALTH 19–24 (1979). 
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radio and television and the FTC announced an even more 
stringent package warning than had been suggested in its 1967 
Report to Congress.94 In the Senate, the focus of their tobacco 
hearings was centered on industry self-regulation.95 As a result of 
regulatory pressure and the growing impacts of the fairness 
doctrine pressure, the tobacco industry voluntarily offered to 
discontinue broadcast advertising—a strategic move to mitigate 
other legislative initiatives.96 In turn, the FTC offered to suspend 
its efforts to require health warnings in cigarette advertisements 
until 1971 if broadcasters voluntarily withdrew cigarette ads.97 
After a long process of hearings and debate, the 91st 
Congress enacted the second major piece of federal tobacco 
legislation: the PHCSA of 1969.98 The legislation contained five 
key parts: (1) the suspension of broadcast media cigarette 
advertising; (2) a change in package label warnings; (3) a 
prohibition on state and local government regulation of tobacco 
advertising; (4) the suspension of FTC action on print advertising 
until July 1, 1971; and (5) a requirement that the FTC and 
DHEW report annually to Congress on the consequences of 
smoking, the effectiveness of labeling, and advertising 
practices.99 While the PHCSA was somewhat more rigorous than 
the FCLAA, the final bill was the product of significant 
compromise and was, no doubt, heavily influenced by the strong 
hand of the tobacco lobby.100 As was the case with the FCLAA, 
the White House appeared to distance itself from the PHCSA. 
The strong support from the public health community, and the 
drive to eradicate cancer that led to the National Cancer Act in 
the following year, marked a political climate that resulted in 
President Nixon signing the new cigarette act on April 1, 1970.101 
On January 1, 1971 at 11:50 p.m., the last cigarette ad ran 
on network television, as what was arguably the most significant 
provision of the PHCSA of 1969 went into effect.102 Television 
cigarette advertising was a hallmark of broadcast media, and 
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 98 Public Health Cigarette Smoking Act of 1969, Pub. L. No. 91-222, 84 Stat. 87 
(codified as amended at 15 U.S.C. §§ 1331–1340 (2012)). 
 99 See id. at 87–89. 
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was seen as a major influence on children.103 In 1970, their final 
year on the airwaves, tobacco manufacturers spent over $200 
million on TV ads.104 But even prior to the U.S. ad ban, strict 
regulation of broadcast tobacco ads in several European 
countries, and an outright prohibition in the UK, appeared to 
have little impact on smoking rates in those countries.105 
Curiously, with the ban on cigarette advertising in place, the 
FCC mandate to require broadcasters to run free public health 
anti-smoking ads was no longer necessary, thereby abrogating 
the use of the fairness doctrine.106 While television ads were 
eliminated, tobacco manufacturers continued their vigorous 
marketing elsewhere.107 They shifted to print media and point of 
sale promotions, as well as various types of product sponsorships.108 
Broadcasters, on the other hand, were faced with significant 
revenue losses and challenged the PHCSA ad ban in court, as 
being in violation of First Amendment commercial speech 
protections, and Fifth Amendment due process rights.109 A three 
judge panel in Capital Broadcasting Co. v. Mitchell disagreed 
with the broadcasters’ legal claims and ruled that commercial 
speech protections were more limited than other forms of 
speech.110 Congress had the power to ban broadcast media 
cigarette advertising based on either its authority over 
regulatory agencies or interstate commerce. The court in Mitchell 
found that the broadcasters’ rights to free speech were not 
violated, as their revenue loss from cigarette ads did not prohibit 
them from commenting on the issue of smoking and public 
health.111 In a dissenting opinion in Mitchell, Judge Skelly 
Wright argued that the ban on cigarette advertising was a 
matter of public importance that should receive full 
constitutional speech protections.112 Judge Wright was 
particularly concerned that the ban on TV and radio advertising 
took the issue off the airwaves and, in so doing, denied the use of 
the fairness doctrine to spark a more balanced discussion of the 
health impacts of cigarettes.113  
 
 103 Lee Lescaze, Cigarette Advertising, WASH. POST (Jan. 15, 1979), 
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The package warning label requirement in the PHCSA was 
not a novel legislative provision as the cigarette ad ban was, but 
rather offered a modest extension of the warning requirement in 
the FCLAA, with the inclusion of language that added the 
gravitas of the U.S. Surgeon General to the package label. The 
original 1965 warning label requirement did not succeed in 
reducing cigarette consumption, but rather than abandoning the 
idea of a consumer warning, subsequent legislative initiatives, 
starting with the 1969 PHCSA, amended the mandatory language 
to make the warnings more detailed.114 The PHCSA prohibited the 
FTC from requiring the cigarette warnings apply beyond package 
labels, but that limitation was only in place until July 1, 1971, and 
once this moratorium had expired, the Commission, which was 
strongly committed to use of consumer warnings, expanded the 
requirement to include all tobacco advertising.115  
The use of a product warning has a dual objective of both 
educating the public about the risks posed by a given product, as 
well as deterring use of the product. Clearly the goal of use 
deterrence was not one that was welcomed by cigarette 
manufacturers and sellers, and so the industry struggled to meet 
the legal warning requirements in ways that minimized their 
impact on sales. On the government side, even with ongoing 
mitigation efforts, there was no centralized voice for tobacco 
control in either the Executive branch or Congress.116 Pockets of 
strong opposition to regulation were sparked by pressure from 
heavy lobbying by tobacco manufacturers and agricultural 
interests.117 The cigarette warning label requirement in the 
PHCSA demonstrated underlying tensions in government 
ranks.118 The regulators in the Executive branch were strong 
supporters of comprehensive oversight, in opposition to views 
sparked by economic concerns in Congress and the White House 
that resulted in favoring more limited approaches to cigarette 
regulation, including minimal package warnings.119  
As previously noted, during the Nixon Administration, 
Surgeon General Steinfeld was an ardent anti-tobacco advocate, 
and specific to tobacco warnings, his views aligned with the 
FTC’s position for much more stringent oversight than what was 
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legislated in the PHCSA.120 On the other hand, as evidenced in a 
1972 Republican memorandum to the attorney general on 
tobacco regulation, concerns were voiced about anti-smoking 
measures that were having a negative impact on political support 
for President Nixon in southern states.121 In the noted 
memorandum, the tobacco industry was praised for its 
willingness to self-regulate and pursue objective scientific 
research into the health aspects of cigarettes.122 Surgeon General 
Steinfeld was characterized as an anti-smoking zealot with a 
vendetta against tobacco that was pursued at the expense of 
dealing with other hazardous substances.123 The warning 
provision in the PHCSA balances countervailing pressures, as 
the package label requirement was driven by a regulatory 
commitment to educate the public about the hazards of smoking, 
a culture of individualism, and a strong desire not to disrupt the 
economic status quo.124  
In his 1968 presidential campaign, President Nixon was 
asked about his opinion on tobacco warnings. The President 
characterized the studies concerning smoking and health as 
controversial, and noted that all the federal government could do 
concerning cigarettes was provide information about smoking 
hazards to the public, and let individuals choose.125 He expressed 
skepticism about whether warnings would have any impact on 
consumer behavior.126 Like the prior Kennedy and Johnson 
administrations, the Nixon White House was very guarded in its 
support of anti-smoking measures, and while Nixon signed the 
PHCSA into law, no fanfare accompanied this signing.127 
IV. BEYOND THE PHCSA: THE TRAJECTORY OF WARNINGS 
At first blush, it appears that the legacy of the PHCSA sinks 
into the sea of laws, regulations, and litigation that developed in 
the area of tobacco control since 1970. Still, the major 
components of the 1969 law—the advertising ban, revised 
warning labels, and preemption of local/state law on 
advertising—were significant steps in the history of tobacco use 
abatement measures that remain relevant in the current 
smoking landscape. Indeed, as the smoking question has 
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expanded into new and different forms of nicotine delivery 
devices beyond traditional cigarettes, the fundamental and 
long-standing regulatory controls found in the PHCSA remain 
viable public health tools in the face of the growing use of 
e-cigarettes and a heightened awareness of the need to control 
health care costs through more effective prevention.  
There are three developments post-1969 concerning smoking 
mitigation that should be noted in tracking the evolution of 
tobacco regulation, dealing directly and indirectly with warning 
labels. First, from the mid-1970s, a major catalyst for ongoing 
smoking regulation was the growing public concern over the 
dangers of cigarette smoking, fueled by an awareness of the 
impacts of secondhand smoke.128 With the emergence of solid 
evidence that non-smokers exposed to cigarette smoke were at 
risk for numerous medical conditions, the public health focus 
over smoking broadened.129 Smoking abatement was no longer 
limited to concerns about individual behavior that centered on 
questions of personal choice, but expanded into a population wide 
problem.130 Numerous laws enacted, at all levels of government, 
prohibited smoking in various indoor and outdoor spaces.131 With 
them came ubiquitous signage declaring no smoking policies.132 
There was also a growing awareness and concern about nicotine 
content in cigarettes, as science emerged that cautioned about 
the addictive nature of this chemical.133  
A second development that affected the direction of warnings 
occurred in 1972 when cigarettes and other tobacco products 
were excluded from the jurisdiction of the Consumer Products 
Safety Commission (“CPSC”), thereby closing an avenue for 
possibly more impactful regulation by another regulatory 
actor.134 In 1973, a request was made to the CPSC to set a 
maximum level of twenty-one milligrams of tar in cigarettes and 
ban any cigarettes exceeding that amount from interstate 
commerce, drawing on the Federal Hazardous Substances Act 
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(“FHSA”) as supporting law.135 According to the General 
Accounting Office (“GAO”), who had been referred the matter by 
the U.S. Comptroller General, the FHSA did not extend to 
cigarettes, and while the CPSC could regulate matters under the 
FHSA generally, tobacco oversight was limited to Congress.136 
Concern about CPSC regulation was great enough to result in 
legislative action that explicitly excluded tobacco regulation from 
the FHSA.137 In addition, tobacco was further excluded from 
inclusion in both the Controlled Substances Act (“CSA”), as well 
as the Toxic Substances Control Act (“TSCA”), in essence leaving 
cigarettes exempt from the oversight of significant consumer and 
worker protection regulatory schemes.138  
A third major development in tobacco control can be found in 
the evolution of smoking litigation that escalated throughout the 
second half of the twentieth century. Often, liability claims at 
state levels raised questions about the impacts of mandated 
warning labels; but, starting with the FCLAA, such state claims 
were preempted, spawning a reliance on alternative causes of 
action.139 It would take several decades, but eventually 
consolidated tobacco litigation culminated in a master settlement 
between states’ attorney generals in 1998.140 The settlement 
resulted in historic payments by the manufacturers to individual 
states and adoption of an array of measures, particularly 
oriented to youth, that restricted cigarette advertising and 
marketing, as well as prohibited industry practices designed to 
hide health information about the dangers of smoking.141  
While the cigarette smoking challenge continued to spark 
new approaches to regulation, the use of warning labels that 
came out of the FCLAA and the PHCSA in the 1960s was not 
abandoned, even in the face of skepticism about the effectiveness 
of warnings on education and prevention.142 A review of the 
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legislative history of tobacco in the 1970s demonstrates that 
there were ongoing efforts to strengthen warning labels in a 
number of proposed federal bills, as well as a recommendation by 
the FTC to expand warnings to include tar and nicotine content 
in both packaging and advertising.143 The FCLAA was amended 
in 1973 to expand package-warning requirements to include little 
cigars.144 In 1981, the FTC, in a report to Congress, concluded 
that the PHCSA health warning language was no longer 
impactful on public knowledge and attitudes about smoking, 
spurring Congress to revisit the labeling issue.145 In 1984, the 
Comprehensive Smoking Education Act (“CSEA,” also known as 
the Rotational Warning Act) was passed.146 This law required 
cigarette packages and advertising to use one of four health 
warnings that included much more explicit language about the 
adverse health effects of smoking.147 The four rotational 
warnings were mandatory for not only packaging, but for all 
advertisements and outdoor billboards.148 The 1984 statute 
contained explicit details about the format of labeling, and 
required that manufacturers and importers submit advertising 
plans for approval to the FTC for each brand of cigarettes.149 
CSEA was an attempt to refocus cigarette control efforts, not 
only by expanding warnings labels, but also by extending 
anti-tobacco educational efforts, tracking cigarette ingredients, 
and facilitating interagency coordination of anti-smoking 
efforts.150 Not long after CSEA was enacted, mandatory package 
warnings were extended to smokeless tobacco products.151 
The rotational warnings on both cigarettes and smokeless 
tobacco became a fixture on cigarette packages. Despite a 
whirlwind of legal and policy developments concerning smoking 
abatement, this regulatory mandate—a vestige from the 
 
http://www.rand.org/blog/2014/09/graphic-warning-labels-on-cigarettes-are-scary-but.html 
[http://perma.cc/3NC2-BX59]. 
 143 Klebe, supra note 93, at 36–40. See also Smoker and Nonsmoker Health 
Protection Act, H.R. 10748, 94th Cong. (1975) (showing an example of proposed federal 
legislation that included expansion of cigarette warnings); H.R. 3827, 93d Cong. (1973) 
(requiring a package label reading, “Cigarette Smoking Is Dangerous to Health and May 
Cause Death From Cancer, Coronary Heart Disease, Chronic Bronchitis, Pulmonary 
Emphysema, or Other Diseases”). 
 144 Little Cigar Act, Pub. L. No. 93-109, 87 Stat. 352, 352 (1973). 
 145 See 1981 FTC ANN. REP. 6. 
 146 Comprehensive Smoking Education Act, Pub. L. No. 98-474, 98 Stat. 2200, 
2201–02 (1984). 
 147 Id. 
 148 Id. 
 149 15 U.S.C. § 1333 (1982), amended by 15 U.S.C. § 1333 (Supp. IV 1982). 
 150 Comprehensive Smoking Education Act, H.R. 3979, 98th Cong. (1984). 
 151 Comprehensive Smokeless Tobacco Health Education Act, Pub. L. No. 99-252, 100 
Stat. 30, 30–31 (1986). 
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1960s—held firm. The skepticism, noted above, about the 
efficacy of cigarette label warnings remained a persistent 
undertone in this area. In a landmark report on tobacco control 
in 2007, the Institute of Medicine (“IOM”) voiced support for the 
use of packaging as an effective vehicle for health 
communications, but concluded that the warnings stemming 
from CSEA were inadequate.152 The IOM called for revised 
warnings to foster greater public awareness of health risks, as 
well as to discourage consumption.153 
The 2007 IOM report was a harbinger of the Family 
Smoking Prevention and Tobacco Control Act of 2009 (“TCA”), 
the most comprehensive federal legislation in the tobacco 
control area to date.154 Congress crafted the TCA based on key 
evidence drawn over several decades.155 Major drivers of the law 
included reducing smoking among children and adolescents, 
recognizing the strong link between smoking and addiction to 
nicotine, and continuing public educational efforts to counter 
tobacco-marketing efforts.156 The TCA established a broad 
framework for ongoing regulation—drawing together in one bill 
an array of measures posited for some time.157 In particular, the 
law designated the federal Food and Drug Administration 
(“FDA”) as the central authority in this area, giving the 
Administration the power to regulate the manufacture, 
distribution, and marketing of cigarettes, cigarette tobacco, 
roll-your-own tobacco, smokeless tobacco, and any other tobacco 
product the Administration deems by regulation to be considered 
a “tobacco product.”158 The 2009 law provides three pathways for 
approval of new tobacco products by the FDA in conjunction with 
its general powers under the Food, Drug, and Cosmetic Act.159 The 
three regulatory pathways include a pre-market approval order for 
all new tobacco products; secondly, a modified risk tobacco product 
 
 152 See INST. OF MED., ENDING THE TOBACCO PROBLEM: A BLUEPRINT FOR THE NATION 
289–96 (Richard J. Bonnie et al. eds., 2007). 
 153 See id. 
 154 See Family Smoking Prevention and Tobacco Control Act, Pub. L. No. 111-31, 123 
Stat. 1776 (2009). 
 155 See id. at 1777–81.  
 156 See Nicopure Labs, L.L.C. v. FDA, 266 F. Supp. 3d 360, 371 (D.C. Cir. 2017). 
 157 See Family Smoking Prevention and Tobacco Control Act—An Overview, U.S. FOOD 
& DRUG ADMIN., http://www.fda.gov/tobacco-products/rules-regulations-and-guidance/family-
smoking-prevention-and-tobacco-control-act-overview [http://perma.cc/EW6G-K37F] (last 
updated Jan. 17, 2018). 
 158 See Federal Food, Drug, and Cosmetic Act, ch. 675, 52 Stat. 1040 (1938) (codified 
as amended in scattered sections of 21 U.S.C.); see also Deeming Tobacco Products to be 
Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking 
Prevention and Tobacco Control Act; Regulations on the Sale and Distribution of Tobacco 
Products, 79 Fed. Reg. 23,142, 23,142 (2014). 
 159 See Federal Food, Drug, and Cosmetic Act, 21 U.S.C. §§ 387j, 387k (2012). 
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category that applies to single products that have been altered to 
modify health considerations; and thirdly, a substantial 
equivalence plan for predicate products that came on the market 
prior to March 2011.160 It is noteworthy that tobacco products that 
were unchanged since entering the market prior to 2007—while 
subject to FDA regulation—are treated as grandfathered brands, 
not requiring specific Administration approval.161 Another 
noteworthy feature of the Act is the requirement that cigarette 
companies disclose all product ingredients, and stop using 
descriptive words like “light” and “ultra-light” to create the 
impression that a particular product is a healthy smoking 
alternative.162 Critics of the TCA voiced concern that the 
legislation comes up short.163 For example, it allows the FDA to 
mandate lower nicotine levels in cigarettes, but by not banning 
this chemical outright, it results in addicted smokers inhaling 
more deeply and increased consumption by these smokers to feed 
their nicotine craving.164  
Perhaps the most significant feature of the TCA is that the 
law, for the first time in twenty-five years, imposes new labels 
and warnings on tobacco packages and on advertisements.165 The 
combined influence of the IOM report’s critique of warnings, 
along with the adoption of more detailed textual warnings, and 
startling graphic depictions of illnesses caused by smoking in 
countries across the globe, spurred a renewed American 
regulatory effort to invigorate the warning process. The 2006 
World Health Organization (“WHO”) Framework Convention on 
Tobacco Control (“FCTC”) called for the use of packaging 
warnings that are rotating, “large, clear, visible and legible,” 
 
 160 See Premarket Tobacco Product Applications, U.S. FOOD & DRUG ADMIN., 
http://www.fda.gov/tobacco-products/market-and-distribute-tobacco-product/premarket-
tobacco-product-applications [http://perma.cc/RQ8K-KJX6] (last updated Oct. 25, 2019); 
Modified Risk Tobacco Products, U.S. FOOD & DRUG ADMIN., http://www.fda.gov/tobacco-
products/advertising-and-promotion/modified-risk-tobacco-products [http://perma.cc/9746-
TVYP] (last updated Oct. 22, 2019); FOOD & DRUG ADMIN., DEMONSTRATING THE 
SUBSTANTIAL EQUIVALENCE OF A NEW TOBACCO PRODUCT: RESPONSES TO FREQUENTLY 
ASKED QUESTIONS (3d ed. Dec. 2016), http://www.fda.gov/media/90811/download 
[http://perma.cc/E76U-D22D].  
 161 For an interesting discussion of the deeming rule, see Introducing the FDA 
Deeming Authority Clarification Act of 2015, 114th Cong. 5694 (Apr. 28, 2015) (statement 
of Hon. Tom Cole). 
 162 See Family Smoking Prevention and Tobacco Control Act, Pub. L. No. 111-31, 123 
Stat. 1776, 1780 (2009). 
 163 Michael Siegel, Tobacco regulations are no regulations at all, L.A. TIMES (June 3, 
2009), http://web.archive.org/web/20161226015412/http://articles.latimes.com/2009/jun/03/ 
opinion/oe-siegel3 [http://perma.cc/7JW7-K79Y]. 
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 165 See Family Smoking Prevention and Tobacco Control Act, Pub. L. No. 111-31, 123 
Stat. 1776, 1842–43. 
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and includes pictures or pictograms.166 Under the TCA, the FDA 
was empowered to require that cigarette packages and 
advertisements bear one of nine new health warnings and that 
the warnings, with graphics, comprise 50% of the front and rear 
panels of cigarette packages.167 The new label warnings are 
linked to the FDA requirements under the Administration’s 
misbranding provisions, which require that a regulated product 
include proper labeling.168 In the case of cigarettes, the product 
would be considered misbranded if it failed to comport with the 
necessary language, placement, typography, and graphics.169 
Congress legislated the nine rotational warnings that were to be 
used, but left the selection of accompanying graphics in the 
hands of the FDA.170 The law allows the FDA to adjust the type 
size, text, and format of cigarette health warnings to ensure that 
the graphics and accompanying text are clear, conspicuous, 
legible, and adequately sized.171  
In deciding which graphic warnings to be used, the FDA 
was tasked with balancing a strategy to discourage nonsmokers, 
especially children, from initiating cigarette use and to 
encourage current smokers to change their behavior in order to 
reduce health risks.172 The Administration analyzed thirty-six 
graphic images drawn from consumer research on health 
communications, considering cognitive and emotional 
reactions.173 The FDA concluded that risk information was best 
communicated through emotional messages, because such 
messages are more likely to garner a reaction from smokers.174 
The Administration settled on nine graphic images to accompany 
each of the new mandated warning statements, together with a 
phone number from the National Cancer Institute’s “Network of 
Tobacco Cessation Quitlines.”175 Selection of the graphic images 
was based on an 18,000-person Internet survey that focused on 
 
 166 WORLD HEALTH ORG., WHO FRAMEWORK CONVENTION ON TOBACCO CONTROL, Art. 
11.1(b) (Feb. 27, 2005).  
 167 15 U.S.C. § 1333 (2012) (The warnings include: “[c]igarettes are addictive”; “[t]obacco 
smoke can harm your children”; “[c]igarettes cause fatal lung disease”; “[c]igarettes cause 
cancer”; “[c]igarettes cause strokes and heart disease”; “[s]moking during pregnancy can 
harm your baby”; “[s]moking can kill you”; “[t]obacco smoke causes fatal lung disease in 
nonsmokers”; and “[q]uitting smoking now greatly reduces serious risks to your health”). 
 168 See Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 387c (2012). 
 169 See id. § 321(n). 
 170 See 15 U.S.C. § 1333. 
 171 See id.  
 172 See Required Packaging Warnings for Cigarette Packages and Advertisements, 
75 Fed. Reg. 69,525 (Nov. 12, 2010). 
 173 See Required Warnings for Cigarette Packages and Advertisements, 76 Fed. Reg. 
36,637–38 (June 11, 2011). 
 174 Id. at 36,639. 
 175 Id. at 36,681. 
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whether the proposed graphic increased the consumer’s desire to 
quit or refrain from smoking, expanded knowledge about the 
risks of smoking and secondhand smoke, and sparked a negative 
reaction.176 In its response to criticisms about the new graphic 
labels, the FDA acknowledged that its study did not permit the 
Administration to reach firm conclusions about long-term effects 
of the proposed warnings, but justified the new regulation based 
on scientific literature and the widespread use of graphic 
warning labels in other countries.177  
Following the issuance of the final rule implementing the 
FDA’s new graphic cigarette package warnings, the tobacco 
companies filed two separate lawsuits. In a suit brought in the 
Western District of Kentucky in Discount Tobacco & Lottery 
v. United States, five tobacco companies and one retailer 
challenged the legality of the 2009 Tobacco Control Act on 
several grounds.178 One such ground claimed that the new 
labeling requirements violated commercial speech rights under 
the First Amendment.179 In overturning a district court grant of 
summary judgment to the corporate plaintiffs resting on the use 
of a First Amendment strict scrutiny standard, the court of 
appeals in the Kentucky case applied a more liberal approach to 
commercial speech that rested on the state’s interest in 
preventing consumer deception.180 The court found that the new 
graphic warnings constituted a form of commercial speech that 
was accurate, salient, and reasonably related to health 
protection.181 Further, it found that the labeling requirement did 
not infringe on the plaintiffs’ speech rights, as either an undue 
burden or an unjustified consumer protection.182 
Another suit was filed by the tobacco industry that 
challenged the legality of the FDA graphic warning label 
regulation, rather than the statutory challenge against the TCA 
 
 176 See id. at 36,637. 
 177 R.J. Reynolds Tobacco Co. v. FDA, 696 F.3d 1205, 1210 (D.C. Cir. 2012), overruled on 
other grounds by Am. Meat Inst. v. U.S. Dep’t of Agric., 760 F.3d 18, 22–23 (D.C. Cir. 2014). 
 178 Disc. Tobacco City & Lottery, Inc. v. United States, 674 F.3d 509, 518 (6th Cir. 2012). 
 179 Id. 
 180 See id. at 522. The court relied on the commercial speech test articulated by the 
U.S. Supreme Court in Zauderer v. Office of Disciplinary Counsel of Supreme Court of 
Ohio. Id. at 523–24 (citing 471 U.S. 626, 627 (1985)). 
 181 See id. at 522–23, 531. 
 182 See id. at 530–31. The court of appeals found that the requirement to include a 
“quit” number on cigarette labels did not fall under the Zauderer standard but should be 
subjected to a more stringent standard of review as it was not designed to directly inform 
consumers, but rather constitutes a smoking mitigation measure. See id. at 522–23. 
Under the more rigorous Central Hudson test, the “quit” number needed greater 
justification to demonstrate it is the most viable mechanism to meet a government goal; 
on its face, the “quit” number contradicts the tobacco company message at the point of 
sale, imposing a significant burden on commercial speech. See id. at 522–23, 544. 
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raised in Discount Tobacco & Lottery. The corporate plaintiffs in 
the D.C. circuit case of R.J. Reynolds v. FDA argued that the 
graphic warning regulation infringed on their First Amendment 
commercial speech rights.183 Unlike the court in Discount 
Tobacco & Lottery, the R.J. Reynolds court applied a First 
Amendment review based on precedents from Zauderer v. Office 
of Disciplinary Counsel of Supreme Court of Ohio, and a more 
challenging commercial speech analysis drawn from the case of 
Central Hudson Gas & Electric v. Public Service Commission.184 
The D.C. court reasoned that purely factual and uncontroversial 
required disclosures per Zauderer were allowed under the First 
Amendment, provided such disclosures were justified and not 
overly burdensome.185 The court’s analysis next included the 
application of elements drawn from Central Hudson, which 
required that in order to restrain free speech, the government 
must demonstrate a valid interest, the advancement of that 
interest in its exertion of regulatory authority, and a showing that 
the regulation in question was narrowly cast.186 The D.C. court 
concluded that the FDA failed to present any data that enacting 
the proposed graphic warnings would accomplish the objectives of 
reducing smoking rates.187 The court found that consumers could 
misinterpret some of the required images, and that others failed to 
convey any warning language at all.188 The R.J. Reynolds court 
vacated the rule and remanded it back to the Administration. 
Following the decision, the FDA withdrew the graphic warning 
rule, even though, as noted, the Western District of Kentucky had 
supported the constitutionality of the TCA.189 Shortly after the 
D.C. decision, the Attorney General of the United States notified 
Congress that the FDA would undertake research to support a 
new rulemaking effort consistent with the Tobacco Control Act.190 
In the interim, the warning label requirements that required a 
textual warning—which had been in place since 1984—remained 
in force. 
The FDA moved very slowly in developing a new 
tobacco-labeling rule, even in the face of its statutory obligation 
 
 183 See R.J. Reynolds, 696 F.3d at 1211. 
 184 See id. at 1217. 
 185 See id. at 1216. 
 186 See id. at 1217. 
 187 Id. at 1219. 
 188 See id. at 1216–17. 
 189 See id. at 1222.  
 190 Letter from Eric Holder Jr., Att’y Gen., to the Honorable John Boehner, Speaker, 
U.S. H.R. (Mar. 15, 2013) (on file with the Univ. of Cal. S.F. Ctr. for Tobacco Control Res. 
& Educ.), http://tobacco.ucsf.edu/sites/tobacco.ucsf.edu/files/u9/Ltr%20to%20Speaker%20 
re%20Reynolds%20v%20FDA.PDF [http://perma.cc/6HDL-QF7N]. 
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under the TCA and a 2012 court decision compelling action in this 
area.191 Frustration with Administration inaction on the part of 
public health advocates resulted in a legal challenge in the United 
States District Court for the District of Massachusetts, which 
alleged that the Administration was unlawfully withholding action 
in its failings to issue new graphic warning labels.192 The action 
sought a court order to compel rulemaking.193  
The Massachusetts Federal District Court in American 
Pediatrics v. FDA ruled in favor of the plaintiff health care 
associations, holding that the Administration unlawfully 
withheld and unreasonably delayed issuing graphic warning 
labels.194 The court found that the Administration failed to justify 
its delay in the face of public health and welfare interests, and 
absent a showing of competing priorities.195 The judge ordered 
the FDA to issue a new proposed rule on graphic cigarette 
warnings in compliance with the TCA by August 15, 2019, with a 
final rule to be completed by March 15, 2020.196  
In August of 2019, eight years after the first notice of 
proposed rulemaking was issued to implement the graphic 
warning provisions of the TCA, the FDA issued a new proposed 
rule in compliance with the federal court order in American 
Pediatrics.197 The Administration proposed thirteen new textual 
health warning label statements “accompanied by color graphics 
depicting the negative health consequences of smoking.”198 These 
new color graphics are required to “appear prominently on 
packages and in advertisements, occupying the top 50 percent of 
the area of the front and rear panels of cigarette packages and at 
least 20 percent of the area at the top of cigarette 
advertisements.”199 The warnings and graphics focus on 
well-known health risks caused by smoking, such as lung cancer 
and heart disease, but also include lesser-known risks, like 
 
 191 See R.J. Reynolds, 696 F.3d at 1222. 
 192 Court Orders FDA to Issue Proposed Graphic Cigarette Warning Rule This Year, 
TROUTMAN SANDERS: TOBACCO L. BLOG (Apr. 24, 2019), http://www.tobaccolawblog.com/ 
2019/04/court-orders-fda-to-issue-proposed-graphic-cigarette-warnings-rule-this-year/ 
[http://perma.cc/BRR7-UF8G]. 
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 194 Am. Acad. of Pediatrics v. FDA, 330 F. Supp. 3d 657, 667 (D. Mass. 2018). 
 195 Id.  
 196 Federal court orders FDA to issue final rule requiring graphic cigarette warnings, TRUTH 
INITIATIVE (Mar. 6, 2019), http://www.truthinitiative.org/press/press-release/federal-court-orders-
fda-issue-final-rule-requiring-graphic-cigarette-warnings [http://perma.cc/N555-EW4Y]. 
 197 See Tobacco Products; Required Warnings for Cigarette Packages and 
Advertisements, 84 Fed. Reg. 42,754, 42,754 (Aug. 16, 2019).  
 198 Id. at 42,757. 
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Do Not Delete 5/22/20 8:51 AM 
80 Chapman Law Review [Vol. 23:1 
bladder cancer and diabetes.200 The FDA developed the new rule 
in the wake of the R.J. Reynolds case, so the commercial speech 
elements in Zauderer and Central Hudson became essential 
parameters in the development of the rulemaking process.201 The 
new rule, driven by the court critiques in R.J. Reynolds, was the 
product of extensive legal, scientific, and regulatory analysis 
resting on an iterative research process that was much more 
detailed than the case made for the 2011 rule.202 The FDA 
regulators posit that the new rule advances a substantial 
government interest and is no more extensive than is 
necessary.203 The Administration believes that its original and 
expansive research provides a basis for the revised cigarette 
warnings that offer consumers’ new information, sparking 
greater understanding about the health risks of smoking, and is 
both more understandable and memorable than prior Surgeon 
General warnings.204 In addition, the FDA was very conscious of 
not mandating warnings that are purely emotional in character, 
but rather took pains to develop labels which simultaneously 
garner attention and convey substantive messages.205 Under the 
dictates of the proposed rule, product manufacturers, distributors, 
and retailers must submit a plan to the FDA for the random 
display and distribution of required warnings on packages.206 The 
thirteen new warning labels and the twelve accompanying 
picture graphics are set to take effect fifteen months after the 
final FDA warning label regulation is in place, which may occur 
in 2021.207 It is conceivable that a new commercial speech 
challenge may be mounted, as the tobacco industry is unlikely to 
cede the marketing benefits of its packaging without a fight. 
V. WARNINGS AND THE DEEMING RULE 
While most of the developments concerning tobacco 
warnings, dating back to the 1970s’ FCLAA and PHCSA, center 
on cigarette packages and advertisements, such mandates also 
extend to other tobacco products and were motivated by evolving 
health concerns. As noted earlier, special textual warning 
requirements for smokeless tobacco products have been in place 
 
 200 See id. at 42,773–76. 
 201 See id. at 42,778–79. 
 202 See id. at 42,778. 
 203 See id. at 42,777–79. 
 204 See id. at 42,772. 
 205 See id. at 42,778. 
 206 Id. at 42,755.  
 207 See id. at 42,784. 
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since 1986.208 In a 2000 FTC settlement, the seven largest 
American cigar manufacturers agreed to include health warnings 
on packaging and in advertisements.209 The settlement led to the 
adoption of one of five textual cigar-smoking warnings.210 The 
most significant expansion of tobacco product warning label 
requirements emerges from the 2009 TCA. Under the TCA, the 
FDA is granted authority to regulate all tobacco products which 
includes cigarettes, cigarette tobacco, roll-your-own tobacco, 
smokeless tobacco, and, very significantly, any other product it 
deems, by regulation, to be a tobacco product.211 The FDA under 
its “deeming” authority is able to apply a very broad definition of 
what a tobacco product is, including “any product made or 
derived from tobacco . . . including any component, part, or 
accessory of a tobacco product . . . .”212 To date, the expanded 
regulatory power includes electronic nicotine delivery systems 
(e-cigarettes and e-liquid), cigars, hookah, and pipe tobacco.213 
The TCA scheme allows tobacco products that were on the market 
prior to 2007 to continue being sold without Administration 
approval, but other tobacco products are subject to regulation, 
either as equivalent to pre-2007 smoking implements or ones that 
must obtain a new tobacco marketing order.214  
In May 2016, under the auspices of the TCA, the FDA 
issued a final deeming rule that established a regulatory floor 
for control of so-called “other tobacco products” (“OTP”), with a 
particular emphasis on electronic nicotine delivery systems.215 
Under the deeming rule, the Administration may use its power 
to restrict the sale, distribution, and promotion of OTPs, 
provided such actions are for public health purposes.216 A key 
feature of this final rule is its focus on the issue of warning 
 
 208 See Comprehensive Smokeless Tobacco Health Education Act of 1986, Pub. L. No. 
99-252, 100 Stat. 30 (codified as amended at 15 U.S.C. §§ 4401–4406, 4408 (2012)). This 
law requires smokeless tobacco product packages and advertisements to include health 
related warning labels on a rotational basis. Id. at 31–32. 
 209 FTC Announces Settlements Requiring Disclosure of Cigar Health Risks, FTC 
(June 26, 2000), http://www.ftc.gov/news-events/press-releases/2000/06/ftc-announces-
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 210 Id. 
 211 21 C.F.R. § 1100.1 (2019). 
 212 21 U.S.C. § 321(rr)(1) (2012). 
 213 See Deeming Tobacco Products to be Subject to the Federal Food, Drug, and 
Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; 
Restrictions on the Sale and Distribution of Tobacco Products and Required Warning 
Statements for Tobacco Products, 81 Fed. Reg. 28,974, 29,028 (May 10, 2016) (to be 
codified at 21 C.F.R. pts. 1100, 1140, and 1143). 
 214 See 21 U.S.C. § 387j (2012). 
 215 Deeming Tobacco Products to be Subject to the Federal Food, Drug, and Cosmetic 
Act, 81 Fed. Reg. at 28,974–75. 
 216 Id. at 28,975. 
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labels.217 The warning requirements in the rule are centered on 
the dangers of nicotine, requiring language that states, “This 
product contains nicotine. Nicotine is an addictive chemical.”218 
Packaging and advertising for cigars must continue to use one 
of five warnings, as well as an addictiveness warning.219 Under 
the deeming rule, health warnings need to appear on at least 
30% of each of the two principal display panels of packaging or 
20% of print advertisements.220 
In its notice of proposed rulemaking for the deeming rule, 
the FDA makes a detailed case in support of tobacco health 
warnings in both packaging and advertisements, to assist 
current and future smokers in understanding the serious adverse 
health consequences of smoking.221 The Administration voices 
concerns it has about consumers’ erroneous and unsubstantiated 
beliefs that tobacco products, other than cigarettes, are less 
addictive or not addictive at all.222 According to the 
Administration, warnings ought to be directed to adolescents, 
whose lack of knowledge about the risks of cigarettes and other 
tobacco products, particularly e-cigarettes, make them very 
susceptible to resultant health risks.223 The FDA strategy 
encompasses OTPs, which pose novel and unfolding health risks, 
as the products have changed in the short time since their 
introduction into the market in 2007.224 The Administration’s 
support of package warnings rests on the frequency of exposure 
to such messages, as warnings are present at the point of 
purchase, time of use, and impacts are likely to extend beyond 
vapers to the public at large.225 Formatting of warning labels and 
ads is a major issue for the Administration, as research shows 
that warnings that are made in small font sizes have a much 
 
 217 See id. at 28,988. 
 218 Id. at 28,979. 
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 223 See id. at 23,146. 
 224 See id. at 23,144. 
 225 Id. at 23,164. 
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lower impact on general consumer awareness than those in 
larger font.226  
Cigar companies and e-cigarette manufacturers pushed back 
against the deeming rule, claiming in a number of lawsuits that 
the regulation was unconstitutional.227 As the Administrative 
Procedures Act and the Regulatory Flexibility Act govern the 
actions of the FDA, typically challenges against the Administration 
rest on allegations of a violation of one or both statutes.228  
In Nicopure Labs, L.L.C. v. FDA, a Florida e-cigarette 
manufacturer alleged in the District Court for the District of 
Columbia that the FDA interpretation of a tobacco product that 
includes e-cigarettes was too broad, and as such, not in 
accordance with the Administrative Procedures Act.229 The 
e-cigarette company argued that premarket certification, 
validation of health benefits, and nicotine warnings were all 
unnecessary.230 A separate challenge in the same district court 
brought by eleven e-cigarette trade groups, including an 
allegation that the deeming rule violated free speech rights 
because of its prohibition on free sample distribution, was 
consolidated with Nicopure.231 In ruling in favor of the FDA, the 
district court concluded that the allegations did not concern the 
details of the deeming rule, but rather focused on statutory 
requirements in the TCA.232 Under the auspices of the TCA, the 
Administration had the necessary statutory authority to subject 
e-cigarette and liquid manufacturers to tobacco product 
regulation, and such action could not be characterized as arbitrary 
and capricious.233 In using the Central Hudson commercial speech 
test noted earlier, the court in Nicopure found that the distribution 
of free samples of e-cigarette products is not sufficiently expressive 
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amended in scattered sections of 5 U.S.C.); Regulatory Flexibility Act, 5 U.S.C. §§ 601–612 (2018). 
 229 Nicopure Labs, L.L.C. v. FDA, 266 F. Supp. 3d 360, 366, 391 (D.D.C. 2017).  
 230 Id. at 367–68 (“This case does not pose the question—which is better left to the 
scientific community in any event—of whether e-cigarettes are more or less safe than 
traditional cigarettes. The Rule did not purport to take the choice to use e-cigarettes away 
from former smokers or other adult consumers; the issue is whether the FDA has the 
authority to require that the choice be an informed one.”). 
 231 Id. at 366. 
 232 Id. at 368.  
 233 Id. at 393. 
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to constitute speech, and thus the FDA has the power, under the 
auspices of the TCA, to restrict such conduct.234  
In July of 2017, the FDA announced a new comprehensive 
plan for tobacco and nicotine regulation to provide a multi-year 
roadmap—specifically to protect children and reduce tobacco 
related disease and death.235 The Administration’s goal is to 
strike a better balance between appropriate oversight of 
smoking, while encouraging development of innovative tobacco 
products that may be less dangerous than cigarettes.236 As part of 
its regulatory effort, the FDA rolled back the implementation of 
the deeming rule to August 2021 for newly regulated tobacco 
products (cigars, pipe tobacco, and hookah tobacco) and to August 
2022 for non-combustible products (“END”).237 As a result of 
litigation challenging the FDA rollback, the new tobacco product 
applications deadline was accelerated to 2020.238 In 2018, the 
Administration issued three advanced notices of proposed 
rulemaking (“ANPR”) dealing with nicotine levels, regulation of 
flavors, and regulation of premium cigars.239 In the case of cigars, 
the ANPR solicited ideas about how current product warnings 
can be strengthened by adding any additional or alternative 
language.240 A major focus of the ANPRs concerns the FDA’s 
interest in establishing maximum nicotine levels that would 
make tobacco products less addictive, or even non-addictive, 
demonstrating that future tobacco abatement efforts will center 
on combating long-term product dependence.241 
 
 234 Id. at 411. 
 235 FDA announces comprehensive regulatory plan to shift trajectory of tobacco-related 
disease, death, U.S. FOOD & DRUG ADMIN. (July 27, 2017), http://www.fda.gov/news-
events/press-announcements/fda-announces-comprehensive-regulatory-plan-shift-trajectory-
tobacco-related-disease-death [http://perma.cc/DJ5H-ZA7D]. 
 236 Id. 
 237 Id. 
 238 See Am. Acad. of Pediatrics v. FDA, 379 F. Supp. 3d 461, 468, 498 (D. Md. 2019), 
appeal docketed, No. 19-2130 (4th Cir. Oct. 16, 2019). The original deadline of 2021 was 
challenged by the Vapor Technology Association (“VTA”), which filed suit on August 14, 
2019, seeking to enjoin the FDA from enforcing its new deadline of 2020. See Verified 
Complaint (Preliminary Injunction Requested) at 2, Vapor Tech. Ass’n v. U.S. Food 
& Drug Admin., No. 5:19-cv-00330-KKC (E.D. Ky. Aug. 14, 2019). The VTA suit was 
subsequently dismissed for lack of standing and causation.  
 239 See Tobacco Product Standard for Nicotine Level of Combusted Cigarettes, 83 Fed. 
Reg. 11,818 (Mar. 16, 2018); Regulation of Flavors in Tobacco Products, 83 Fed. Reg. 
12,294 (Mar. 21, 2018); Regulation of Premium Cigars, 83 Fed. Reg. 12,901 (Mar. 26, 2018).  
 240 See Regulation of Premium Cigars, 83 Fed. Reg. at 12,903. 
 241 See Tobacco Product Standard for Nicotine Level of Combusted Cigarettes, 83 Fed. 
Reg. at 11,819. 
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VI. WARNINGS AND VAPING 
Cigarette labeling requirements are part of the universe of 
increasingly ubiquitous consumer product warnings, driven both 
by general product liability concerns and statutory health 
mandates.242 Since their inception in the 1960s, cigarette label 
and advertisement regulations have been a core element of the 
tobacco use mitigation strategy. With the emergence of OTPs 
(e-cigarettes, heat not burn) in recent years, subject to the FDA’s 
expanded authority through the deeming rule, the issue of 
product warnings arises not as a historical curiosity, but rather 
as a matter of immediate policy concern. Unlike cigarettes, the 
newer ENDs products use an e-liquid, varying compositions of 
chemical flavorings, propylene glycol, as well as vegetable 
glycerin.243 Typically these products contain some level of 
nicotine and come in a dizzying assortment of flavors.244 OTPs 
are not a single product, but are multiple devices that allow users 
to inhale an aerosol that simulates cigarette smoke.245 
Proponents of e-cigarettes advocate for their use as a safer choice 
than cigarettes, and promote ENDs as smoking cessation 
devices.246 Taking a page from big tobacco, e-cigarette companies 
have combined clever marketing and use of sweet flavor additives 
to make these products extremely popular with school-aged 
children.247 The rapid rise in adolescent vaping that may result 
in a new generation of nicotine addiction—reversing progress in 
 
 242 See Thomas Whiteside, Cutting Down, NEW YORKER (Dec. 11, 1970), 
http://www.newyorker.com/magazine/1970/12/19/the-fight-to-ban-smoking-ads 
[http://perma.cc/K2F7-H2RG]. 
 243 See Vaporizers, E-Cigarettes, and other Electronic Nicotine Delivery Systems (ENDS), 
U.S. FOOD & DRUG ADMIN. (Sept. 12, 2019), http://www.fda.gov/tobacco-products/products-
ingredients-components/vaporizers-e-cigarettes-and-other-electronic-nicotine-delivery-
systems-ends [http://perma.cc/2PC4-MFL6].  
 244 But see Do E-Cigs Contain Nicotine?, VAPEMOUNTAIN.COM (Apr. 20, 2016), 
http://www.vapemountain.com/news/do-e-cigs-contain-nicotine.html [http://perma.cc/Q6JJ-
BMVV] (noting that varying levels of nicotine are available in these products). 
 245 See What Do We Know About E-cigarettes?, AM. CANCER SOC’Y, 
http://www.cancer.org/cancer/cancer-causes/tobacco-and-cancer/e-cigarettes.html 
[http://perma.cc/4V3A-XSH4] (last updated Sept. 26, 2019).  
 246 See Michael Joseph Blaha, 5 Vaping Facts You Need to Know, JOHNS HOPKINS MED., 
http://www.hopkinsmedicine.org/health/wellness-and-prevention/5-truths-you-need-to-know-
about-vaping [http://perma.cc/QU3V-KB93] (last visited Oct. 13, 2019). 
 247 See id. The CDC estimated that between 2011 and 2015 the use of e-cigarettes among 
high school and middle school children increased by 900%. Surgeon General’s Advisory on 
E-cigarette Use Among Youth, CTRS. FOR DISEASE CONTROL & PREVENTION, 
http://www.cdc.gov/tobacco/basic_information/e-cigarettes/surgeon-general-advisory/index.html 
[http://perma.cc/Y8UW-L5VP] (last reviewed Apr. 9, 2019). Several states are suing e-cigarette 
manufacturers for targeting children through deceptive marketing practices. See Naomi Martin, 
Healey files lawsuit against JUUL, alleging a campaign to lure underage teens, BOS. GLOBE, 
http://www.bostonglobe.com/2020/02/12/metro/ag-files-lawsuit-against-juul-alleging-campaign-
lure-underage-teens/ [http://perma.cc/3A7E-ZMTT] (last updated Feb. 12, 2020, 12:16 PM). 
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smoking abatement—is a driving force in public health 
prevention, underpinning FDA action in the OTP arena.248  
This growing concern over youth vaping escalated in 2019 
as the CDC reported 1,604 lung injury cases in forty-nine 
states, which included thirty-four deaths in twenty-four states, 
with the common denominator linking these cases being the 
inhalation of vapors from ENDs products.249 The vaping-related 
hospitalizations triggered heightened government scrutiny of 
e-cigarettes, led by both the FDA and the Centers for Disease 
Control and Prevention (“CDC”).250 A few local and state 
governments, following San Francisco’s lead, have placed an 
outright ban on the sale of e-cigarettes in light of the mysterious 
outbreaks of serious pulmonary injury.251 A more common 
regulatory reaction against ENDs is likely to result in 
comprehensive bans on the use of flavor additives such as 
menthol; both the White House and the FDA are supporting 
flavor bans.252 
 
 248 See id. 
 249 Outbreak of Lung Injury Associated with E-Cigarette Use or Vaping, Products, 
CTRS. FOR DISEASE CONTROL & PREVENTION, http://www.cdc.gov/tobacco/basic_ 
information/e-cigarettes/severe-lung-disease.html [http://perma.cc/HJY4-7CTF] (last 
visited Nov. 10, 2019); see also Sydney Lupkin & Anna Maria Barry-Jester, Mysterious 
Vaping Lung Injuries May Have Flown Under Regulatory Radar, KAISER HEALTH NEWS 
(Aug. 27, 2019), http://khn.org/news/mysterious-vaping-lung-injuries-may-have-flown-
under-regulatory-radar/ [http://perma.cc/783P-PZ5T]. In October 2019, the CDC issued 
new guidelines for vaping related lung injuries, classifying the condition as EVALI 
(e-cigarette or vaping product use associated lung injury). See 68 Morbidity and Mortality 
Weekly Report 919–27 (2019). 
 250 See CDC, FDA, States Continue to Investigate Severe Pulmonary Disease Among 
People Who Use E-cigarettes, CTRS. FOR DISEASE CONTROL & PREVENTION (Aug. 21, 2019), 
http://www.cdc.gov/media/releases/2019/s0821-cdc-fda-states-e-cigarettes.html 
[http://perma.cc/A8AP-ZF3Q].  
 251 See Victoria Colliver, In California, Juul’s problems are only beginning, POLITICO 
(Sept. 17, 2019, 5:01 AM), http://www.politico.com/story/2019/09/17/juul-cigarettes-trump-
california-san-francisco-1730095 [http://perma.cc/Z2XA-MSFD]; see also CNN NEWSOURCE, 
Vape store owners are suing to stop the product bans in New York and Massachusetts, NEWS 
CHANNEL 5 NASHVILLE (Oct. 7, 2019, 9:58 AM), http://www.newschannel5.com/news/ 
national/vape-store-owners-are-suing-to-stop-the-product-bans-in-new-york-and-massachusetts 
[http://perma.cc/E9KY-5CJN]; Vapor Technology Association Files Lawsuit Against New York 
Department of Health and Public Health and Health Planning Council to Stop Ill-Considered 
Flavor Ban, CISION: PR NEWSWIRE (Sept. 25, 2019), http://www.prnewswire.com/news-
releases/vapor-technology-association-files-lawsuit-against-new-york-department-of-health-and-
public-health-and-health-planning-council-to-stop-ill-considered-flavor-ban-300925566.html 
[http://perma.cc/N2VS-2K2D]; Read the Lawsuit: Vape Shops Sue to Overturn Gov. Charlie 
Baker’s Four-Month Ban on Sale of Vaping Products, MASSLIVE (Oct. 2, 2019), 
http://www.masslive.com/news/2019/10/read-the-lawsuit-vape-shops-sue-to-overturn-gov-charlie-
bakers-four-month-ban-on-sale-of-vaping-products.html [http://perma.cc/RJ23-J4H8]. 
 252 See Colliver, supra note 251; see also Andrew B. Meshnick et al., How FDA Can Act 
On E-Cigarettes And Protect The Public Health, HEALTH AFFAIRS (Sept. 17, 2019), 
http://www.healthaffairs.org/do/10.1377/hblog20190916.952475/full/ [http://perma.cc/FHZ7-
U4FS]. The crackdown on vaping coming from the Executive branch narrowly focuses on 
reusable (rechargeable) vaping devices and does not cover cheaper disposable products 
which are readily available and come in an assortment of flavors. See Matthew Perrone, FDA 
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Two realities define the current public health efforts to 
combat the ills of smoking and reduce the resultant addiction to 
nicotine, combining to make this long-standing task a type of 
double bind for regulators. On one hand, health authorities face 
the ongoing challenge of traditional smoking health problems, 
and even in the face of significant reduction in this behavior, 
there is a seemingly intractable number of smokers who pursue 
this addiction, unmoved by long standing abatement strategies. 
On the other hand, public health authorities must now cope with 
the development of new tobacco products.253 The rapid growth in 
use of e-cigarettes, particularly among young people, poses new 
and novel challenges for anti-smoking advocates.254 Recent 
events underscore the lack of comprehensive scientific knowledge 
about the short and long-term physiological implications of ENDs 
use, underscoring the critical need for research in this area.255 
There is, however, enough evidence currently to conclude that 
e-cigarettes are a nicotine delivery device that can result in 
addiction and easily act as a gateway to more traditional cigarette 
smoking.256 Compounding the challenge of e-cigarettes is their 
increasing use by adult smokers as a seemingly safer alternative 
to traditional cigarette257—an idea that is being endorsed with a 
dearth of evidence.258 The power of a global tobacco industry as it 
moves into ENDs products, along with a host of new smoking 
options, present formable challenges to overtaxed public health 
regulators trying to keep up with the new developments and 
strength of the tobacco industry.259 An already highly profitable 
 
crackdown on vaping flavors has blindspot: disposables, AP NEWS (Feb. 7, 2020), 
http://apnews.com/600c4aa443dde043aad6f70a00251fa0 [http://perma.cc/H2ZE-7E8L]. 
 253 See Ana Aceves, Vaping May Lead Teens to Adopt Smoking Habits, PBS 
SOCAL (Mar. 15, 2018), http://www.pbs.org/wgbh/nova/article/vaping-teen-smoking-
habit/ [http://perma.cc/JEN3-Y6XJ]. 
 254 See id. 
 255 See Outbreak of Lung Disease Associated with the Use of E-Cigarette, or Vaping Products, 
CTR. FOR DISEASE CONTROL & PREVENTION, http://www.cdc.gov/tobacco/ basic_information/e-
cigarettes/severe-lung-disease.html [http://perma.cc/HJY4-7CTF] (last visited Oct. 13, 2019). 
 256 See Aceves, supra note 253. 
 257 See id. 
 258 See id. 
 259 The e-cigarette industry has taken a page from tobacco manufacturers, developing 
clever marketing strategies to attract youth to their products. See E-Cigarette Marketing 
Continues to Mirror Cigarette Marketing, CAMPAIGN FOR TOBACCO FREE KIDS: BLOG 
TOBACCO UNFILTERED (June 17, 2015), http://www.tobaccofreekids.org/blog/2015_06_17 
_ecig [http://perma.cc/F73L-8Q7J]. A significant amount of e-cigarette marketing is done 
via social media sites geared toward children and young adults, in which product 
warnings and age restrictions are minimized. See Rick Nauert, Aggressive Online 
Marketing of E-cigarettes May Target Teens, PSYCHCENTRAL (Aug. 8, 2018), 
http://psychcentral.com/news/2015/10/05/aggressive-online-marketing-targets-teens-for-e-
cigarettes/93128.html [http://perma.cc/CZH9-9T2L]. 
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cigarette industry is reinventing itself, setting the stage for new 
chapters in smoking abatement battles.260 
As noted in the beginning of this Article, effective health 
prevention and promotion is essential to the future of our health 
system. Addressing population health challenges, like smoking 
and accompanying nicotine addiction, have strong medical and 
economic implications. Unless more effective approaches are 
developed to reduce major preventable public health problems, no 
systemic reform, whatever its character, will find the elusive 
balance between cost and quality. To combat the ills of smoking 
in its traditional and evolving forms, health authorities will need 
to continue to apply established rules, as well as pursue new 
approaches to regulation that have the capacity to reduce and 
possibly eradicate this behavior.261 As such, assessment of 
abatement tools, such as product warnings, should be ongoing as 
public health enforcement strategies must be adjusted to meet 
current challenges, particularly in fluid areas like smoking.  
In reviewing the history of tobacco regulations over the past 
sixty years, mandatory product health warnings designed to 
educate and deter consumption can be characterized as a 
fundamental and lasting approach to smoking abatement. The 
review of cigarette warning labels in this piece demonstrates 
movement in regulation from modest textual warning 
requirements in the 1960 laws, such as the Public Health 
Cigarette Smoking Act, to the expansion of four rotational 
warnings in the 1984 CSEA, and, more recently, to further 
textual warnings and the addition of picture graphics in the 2009 
TCA. While this movement is hardly rapid, it does reflect a 
deeper understanding of the array of tobacco research and 
expansion of knowledge about the physiological effects of 
smoking, with a greater current focus on nicotine exposure from 
OTPs, as well as a sustained commitment to the viability of 
warnings as a key public health measure. 
 
 260 It is estimated that the e-cigarette market in 2018 in the United States was worth 
$11.26 billion and is estimated, by 2024, to grow to $18.12 billion, with an increase in 
online sales. See E-Cigarette Market—Growth, Trends and Forecast (2019–2024), MORDOR 
INTELLIGENCE, http://www.mordorintelligence.com/industry-reports/global-e-cigarettes-
market-industry [http://perma.cc/XE2Z-CQE7] (last visited Oct. 13, 2019); see also Josh 
Constine, How Juul made vaping viral to become worth a dirty $38 billion, TECH CRUNCH 
(Dec. 22, 2018, 10:58 AM), http://techcrunch.com/2018/12/22/juul-me-twice-shame-on-you/ 
[http://perma.cc/BQ5L-4RPA]. 
 261 For a discussion on a British perspective on smoking eradication, a goal that 
transcends borders, see Jason Murugesu, Will we ever stamp out smoking entirely?, NEW 
STATESMAN AM. (Aug. 1, 2019), http://www.newstatesman.com/politics/health/2019/08/ 
will-we-ever-stamp-out-smoking-entirely [http://perma.cc/RDW7-HE8M]. 
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But nagging questions emerge from a review of tobacco 
product label warnings. Are tobacco-warning labels necessary? 
Are labels effective vehicles to inform and deter smoking? Can 
changes be made in tobacco product labels to make them more 
impactful? How should warnings be approached in the new 
landscape of OTPs? Concerning the question of whether there is 
a need to have warning labels, there are simply no voices of 
opposition to these warnings.262 They have garnered universal 
domestic and international support as a core enforcement 
mechanism from public health policy makers and regulators 
alike.263 While product manufacturers and sellers may not 
appreciate text warnings on packaging, there is no push back 
from this sector on this requirement—on the menu of possible 
controls, it does not impose a serious marketing impediment.264 In 
fact, the e-cigarette manufacturers of their own accord, independent 
of government directives, added a nicotine-warning label in 
anticipation of the eventuality of such a mandate, and more 
importantly, as a mechanism to deter product liability litigation.265  
The second question as to whether cigarette-warning labels 
actually work opens a more controversial line of inquiry. Perhaps 
President Nixon’s guarded opinion about cigarette warnings, 
noted earlier in this piece, was noteworthy as to the 
government’s responsibility to notify the public about known 
dangers and let individuals choose to smoke or not.266 President 
Nixon characterized the science driving warnings as 
controversial, but currently, with the exception of e-cigarettes, 
the case against traditional tobacco is definitive, and the quest to 
avoid dangers to health through safe cigarette alternatives still 
remains a Sisyphean one.267  
President Nixon’s other observation expressing doubt about 
the effect of cigarette warnings on the public mirrors long 
standing opinions on both sides of the smoking issue. As noted in 
prior discussion, regulators, as early as 1967, frequently vented 
their frustrations about the textual package warnings, and in 
 
 262 See Abby Ohlheiser, Big tobacco companies are putting big warning labels on their 
e-cigarettes, WASH. POST (Sept. 29, 2014, 10:21 AM), http://www.washingtonpost.com/ 
news/to-your-health/wp/2014/09/29/big-tobacco-companies-are-putting-big-warning-labels-
on-their-e-cigarettes/ [http://perma.cc/L55A-ZZHX]. 
 263 See id. 
 264 See id. 
 265 See id. 
 266 See Whiteside, supra note 242. 
 267 See Laurie McGinley, Forget Those Occasional Cigarettes: There is No Safe 
Smoking Level, WASH. POST (Dec. 5, 2016, 8:00 AM), http://www.washingtonpost.com/ 
news/to-your-health/wp/2016/12/05/forget-those-occasional-cigarettes-there-is-no-safe-
smoking-level/ [http://perma.cc/R23E-JUUV]. 
Do Not Delete 5/22/20 8:51 AM 
90 Chapman Law Review [Vol. 23:1 
fact, an outpouring of criticism about the ineffectiveness of such 
regulation preceded every major tobacco bill.268 The U.S., once 
the leader in mandating tobacco warnings, fell behind in smoking 
controls as other nations implemented graphic warning label 
requirements, spurred by global tobacco abatement policies 
adopted in the WHO’s Framework Convention on Tobacco 
Control.269 Eventually in 2009, with the passage of the TCA, the 
U.S. joined the global community in finally requiring graphic 
warning labels.270 However, as discussed, the regulatory efforts 
in the U.S. to implement graphic warnings have been stormy, 
unsettled, and delayed. 
Confronting the analytical question of whether text only or 
graphic warnings work better to prevent and deter smoking 
behavior places one into the murky waters of behavioral 
economics. Some studies on the effectiveness of tobacco warnings 
on youth and adult smokers conclude that textual warnings may 
increase health knowledge and awareness of risk based on size 
and design, but, at best, the results are tepid.271 
On the other hand, studies concerning the impacts of graphic 
package warning labels are more positive.272 One mega analysis 
of the area concluded that graphic anti-smoking warnings could 
elicit “maladaptive psychological responses”—in other words, 
they could work.273  
No doubt package-warning labels offer a relatively 
inexpensive mechanism to communicate with smokers at the 
point of purchase; however, isolating the impacts of pictorial 
warnings on behavior reduction, independent of other regulatory 
controls, is largely a matter of speculation. Support for warnings 
 
 268 See Luca Paoletti et al., Current Status of Tobacco Policy and Control, 27 J. 
THORACIC IMAGING 213, 215 (2012) (“A 1967 FTC report concluded that ‘the warning label 
on cigarette packages has not succeeded in overcoming the prevalent attitude toward 
cigarette smoking created and maintained by the cigarette companies through their 
advertisements, particularly the barrage of commercials on television, which portray 
smoking as a harmless and enjoyable activity that is not habit forming and involves no 
hazards to health.’”). 
 269 WORLD HEALTH ORG., supra note 166, at 9–10.  
 270 See Family Smoking Prevention and Tobacco Control Act, Pub. L. 11, 123 Stat. 
1776 (codified as amended in 21 U.S.C. §§ 387, 387a–387u, 387a–1, 387f–1 (2012)).  
 271 See David M. Erceg-Hurn & Lyndall G. Steed, Does Exposure to Cigarette Health 
Warnings Elicit Psychological Reactance in Smokers?, 41 J. APPLIED SOC. PSYCHOL. 219, 
230 (2011); see also William G. Shadel et al., Do Graphic Health Warning Labels on 
Cigarette Packages Deter Purchases at Point-of-Sale? An Experiment with Adult Smokers, 
34 HEALTH EDUC. RES. 321, 321–31 (2019). The Shadel article notes that various types of 
analyses on textual and pictorial tobacco warnings have found that pictorial warnings are 
recalled more readily, generate more negative cognitions about smoking, and have greater 
impacts on prevention and smoking reduction. Id. 
 272 See Erceg-Hurn & Steed, supra note 271, at 219. 
 273 See id. 
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rests as much on intuition as fact. Review of American regulatory 
history demonstrates that there is a long-standing belief that 
textual warnings have little effect overtime—the use of graphic 
labels has been delayed for almost ten years, so, as yet, there is 
no experience with graphics in the U.S. American cigarette 
marketplace. Perhaps a better gauge about the impacts of 
warnings can be drawn from the reactions to expanded warning 
labels on the part of the smoking industry. As text warnings are 
relatively benign, occupying a side panel of cigarette packs, 
displayed in similar fonts and colors blending with the overall 
container, they became predictable and easily ignored. Graphic 
warnings, on the other hand, featuring jarring images that 
essentially change the character of the product package, have not 
been met with industry acquiescence, but rather sparked 
vigorous legal challenges that have foiled this initiative for over a 
decade, which could be indicative of the fact that they may 
actually work. 
It is possible to envision an even more stringent and detailed 
tobacco warning label requirement than the August 2019 graphic 
warnings proposed rule, akin to labeling mandates for 
over-the-counter drugs.274 Another direction that could be taken 
is to adopt the approach of Australia and a number of other 
countries that requires cigarettes to be sold in plain packages, 
containing only a warning, without signature brand designs.275 
While plain packaging could be in our future, at this point, 
graphic warning labels need to be adopted and their effectiveness 
assessed over a number of years. Such regulatory impact 
assessments need to occur in a more regular and timely manner 
than was the case with prior warning label analyses and should 
be based on more grounded methodological determinations of 
costs and benefits. The fact that label warnings have been used 
for many years should not establish them as permanent 
regulatory strategies that are not frequently revisited and 
updated—or even abandoned if they have lost their efficacy. 
It would be wrong to suggest that the FDA has been a totally 
absent regulator in the vaping arena.276 Since issuing the 
 
 274 See The Over-the-Counter Medicine Label: Take a Look, U.S. FOOD & DRUG 
ADMIN., http://www.fda.gov/drugs/resources-you-drugs/over-counter-medicine-label-take-
look [http://perma.cc/T3L7-SYBA] (last reviewed Sept. 27, 2017).  
 275 See Thomas Parker, From Uruguay to Saudi Arabia: 14 countries that have 
implemented plain tobacco packaging, NS PACKAGING (May 28, 2019), 
http://www.nspackaging.com/analysis/plain-tobacco-packaging/ [http://perma.cc/8C8F-5HEH]. 
 276 See Katie Thomas & Sheila Kaplan, E-Cigarettes Went Unchecked in 10 Years of 
Federal Inaction, N.Y. TIMES (Oct. 14, 2019, 5:12 PM), http://www.nytimes.com/2019/ 
10/14/health/vaping-e-cigarettes-fda.html [http://perma.cc/YT32-E7H3]. 
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deeming rule in 2016,277 the Administration’s Center for Tobacco 
Products (“CTP”) has moved on a number of fronts to address 
labeling, manufacturing, and marketing of ENDs products.278 In 
particular, emphasis has been placed on preventing youth sales 
and use; conducting retailer and manufacturer checks; developing 
product premarket authorization policies; and sponsoring and 
promoting research.279 In addition, the FTC is also involved in 
e-cigarettes, as it continues its traditional role in policing unfair 
and deceptive practices in the tobacco products arena.280 However, 
the recent outbreaks of serious lung damage in vapers rightly calls 
into question the adequacy of the current regulatory structure.281  
The question arises as to whether the centralized regulatory 
structure of the 2009 TCA is optimal to meet the challenges 
posed by vaping—a practice that was barely in existence when 
the TCA was enacted. Vaping-related lung disease, also known as 
EVALI, has cast a bright light on the potential hazards in 
e-liquids, sparking an awareness of both the complexity and lack 
of knowledge of the underlying health exposures.282 While 
uniformity in federal regulatory approaches to e-cigarettes is 
ultimately desirable, given this lack of certainty about the safety 
of these diverse products and nicotine delivery devices, it may be 
desirable to consider involvement of other regulatory actors, and 
processes in framing warning labels in the ENDs area.283 It is 
noteworthy that in the 2020 Trump-proposed federal budget 
there is a recommendation that a new tobacco control agency be 
created in the Department of Health and Human Services, 
stripping the FDA of this responsibility.284 
 
 277 The decision to regulate combustible cigarettes as tobacco products, primarily 
under FDA auspices, is the result of many years of effort to centralize tobacco regulation 
that culminated in the 2009 TCA.  
 278 See Ned Sharpless, How FDA is Regulating E-Cigarettes, U.S. FOOD & DRUG ADMIN., 
http://www.fda.gov/news-events/fda-voices-perspectives-fda-leadership-and-experts/how-fda-
regulating-e-cigarettes [http://perma.cc/ZB8P-LZ7J] (last updated Sept. 10, 2019). 
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WALL STREET J. (Aug. 29, 2019), http://www.wsj.com/articles/juuls-marketing-practices-
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 281 See Michael Siegel, POV: New FDA Regulations on Vaping Products a Failure, 
BU TODAY (July 13, 2016), http://www.bu.edu/articles/2016/fda-vaping-regulations 
[http://perma.cc/VBB8-N7FG]. 
 282 See Jennifer E. Layden et al., Pulmonary Illness Related to E-Cigarette Use in 
Illinois and Wisconsin—Preliminary Report, NEW ENG. J. MED. (Sept. 6, 2019), 
http://www.nejm.org/doi/full/10.1056/NEJMoa1911614 [http://perma.cc/K89Y-ND2L]. 
 283 See What is Vaping?, VAPING, http://vaping.org/ [http://perma.cc/DD6P-8XSX] (last 
visited Oct. 13, 2019). 
 284 Nicholas Florko, Trump Doesn’t Want the FDA to Regulate Tobacco, STAT (Feb. 
10, 2020), http://www.statnews.com/2020/02/10/trump-doesnt-want-the-fda-to-regulate-
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proposal with certainty. On the one hand, the FDA can be seen as a tepid regulator, slow 
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The FDA regulatory scheme for e-cigarette products follows the 
dictates of the 2009 TCA and is actualized through the 
Administration’s deeming rule. Other regulatory avenues within 
the Food, Drug, and Cosmetic Act (“FDCA”) have not been pursued 
since the Supreme Court decision in FDA v. Brown & Williamson 
that held that tobacco products, as marketed, could not be 
regulated under the FDCA, triggering the subsequent enactment 
of the TCA.285 While the Brown & Williamson case appears to be 
superseded by the TCA, the 2009 regulatory scheme does not allow 
tobacco products, without therapeutic value, to be explicitly 
regulated as either a drug or medical device.286 A federal court in 
Sottera v. FDA reiterated Brown & Williamson in upholding an 
e-cigarette manufacturer’s argument that their products could not 
be regulated separate from the TCA.287 At issue in Sottera was 
whether e-cigarettes could be regulated as unapproved drug device 
combinations.288 It is noteworthy that a key factor in the Sottera 
analysis limiting the FDA’s authority is that the product at issue 
was not being sold for therapeutic purposes, but rather 
recreational.289 The conclusion can be made that a device sold for 
therapeutic purposes would fall within the ambit of 
Administration oversight as a drug/medical device.290 It is evident 
that e-cigarettes are being promoted to adults for smoking 
cessation, and as such, may be regulated as a type of medical 
device.291 This opens the door to another possibility, beyond the 
TCA scheme, for additional e-cigarette FDA action—such as 
 
to act against the threats posed by the explosion in e-cigarettes, and generally 
overwhelmed by its overall mandates. But on the other hand, the FDA tobacco regulatory 
structure is well developed and embodies the requisite authority to be a meaningful public 
health authority in the e-cigarette arena. Creating a new regulatory body may only serve 
to further delay necessary oversight at a time when both the products and their markets 
are far ahead of government control. 
 285 FDA v. Brown & Williamson Tobacco Corp., 529 U.S. 120, 143 (2000). 
 286 See Clarification of When Products Made or Derived From Tobacco Are Regulated 
as Drugs, Devices, or Combination Products; Amendments to Regulations Regarding 
“Intended Uses,” 82 Fed. Reg. 2,193 (Jan. 9, 2017) (to be codified at 21 C.F.R. pts 201, 801, 
and 1100). 
 287 Solterra, Inc. v. FDA, 627 F.3d 891, 897–98 (D.C. Cir. 2010). 
 288 See id. at 892.  
 289 See id. at 898. Therapeutic purposes under the FDCA include use in the diagnosis, 
cure, mitigation, treatment, or prevention of disease, according to 21 U.S.C. § 321 (g)(1) 
(2018). See id. at 893–94. 
 290 See Clarification of When Products Made or Derived From Tobacco Are Regulated 
as Drugs, Devices, or Combination Products; Amendments to Regulations Regarding 
“Intended Uses,” 82 Fed. Reg. 2,193. 
 291 See Esther Wang, Juuling Is Fine, Actually (For Adults Who Want to Quit 
Smoking Cigarettes), JEZEBEL (Sept. 30, 2019, 2:05 PM), http://jezebel.com/juuling-is-
fine-actually-for-adults-who-want-to-quit-1838622453 [http://perma.cc/Z9EU-FDZM]; see 
also Belinda Borrelli & George T. O’Connor, E-Cigarettes to Assist with Smoking 
Cessation, 380 NEW ENG. J. MED. 678, 678 (Feb. 14, 2019), http://www.nejm.org/doi/ 
full/10.1056/NEJMe1816406 [http://perma.cc/8N52-4TUN]. 
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regulating ENDs as over-the-counter medical devices. As an OTC 
device, it is comparable to other tobacco prevention products. 
ENDs devices and e-liquids would need to meet more detailed 
labeling requirements under FDA-OTC regulations.292 Under 
device labeling mandates, the FDA can tailor an OTC product 
label to include additional information that is specific to a given 
health concern and make revisions as new research unfolds. 
Presently, the FDA can move closer to declaring an OTP as 
“safer” if the product undergoes a more rigorous review and 
demonstrates a lower risk to smokers (“MRTP,” or modified risk 
tobacco product).293 It is unclear, however, if an MRTP approval 
can allow the OTP manufacturer to claim that the ENDs device 
is actually a smoking cessation device.294 Such a claim goes 
beyond a stipulation that the smoking product is “safer” into the 
realm of medical devices.295 
Vaping entails igniting a chemical cocktail of ingredients, 
some of which may be quite harmful.296 As such, regulatory 
oversight could benefit from expanding e-cigarettes into the 
purview of the Federal Hazardous Substances Act (“FHSA”), 
under the jurisdiction of the U.S. Consumer Products Safety 
Commission (“CPSC”).297 The current FDA deeming rule could be 
strengthened by inclusion of an additional warning mandate 
focused on chemical exposure; a joint agency-labeling scheme with 
input from the CPSC concerning hazardous chemicals content 
would be a more robust labeling scheme. It appears that vaping 
chemicals meet the criteria required for application of labeling 
mandates under the FHSA.298 At the time cigarettes were 
excluded from FHSA jurisdiction by Congress, smoking products 
did not extend beyond use of plant-based medium, but now clearly 
fall into the realm of hazardous chemicals.299 Broadening CPSC 
 
 292 See General Device Labeling Requirements, U.S. FOOD & DRUG ADMIN., 
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 296 See Carley Thompson, Meet the 5 Chemicals You Didn’t Know Were in Vaping 
Products, PUB. HEALTH INSIDER (June 14, 2017), http://publichealthinsider.com/2017/06/ 
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Problem, U.S. NEWS (Sept. 30, 2019, 9:00 AM), http://www.usnews.com/news/healthiest-
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[http://perma.cc/QTZ2-CEJX]. 
 297 See Federal Hazardous Substances Act, 15 U.S.C. § 1261 (2012).  
 298 See Federal Hazardous Substances Act (FHSA) Requirements, CPSC, 
http://www.cpsc.gov/Business--Manufacturing/Business-Education/Business-Guidance/ 
FHSA-Requirements/ [http://perma.cc/D3EY-BWVX] (last visited Oct. 28, 2019). 
 299 Klebe, supra note 93, at v.  
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jurisdiction to include e-cigarette regulation builds on existing 
Commission authority to regulate e-liquid containers.300  
Warning label jurisdiction should be expanded to the state 
level in keeping with the TCA, which generally carves out a 
greater role for state and local government involvement in 
tobacco regulation. During this period of uncertainty, it seems 
reasonable for states to have authority to add their own warning 
language to e-cigarette products, provided a given state can make 
the case that the additional information being added to a 
warning fosters public health interests. Unlike traditional 
cigarettes, where regulation is the byproduct of years of study, 
the uncertainties surrounding ENDs products could benefit from 
regulatory initiatives warranting experiments with use of a 
variety of OTP warning labels. 
Warning labels are only one strategy that can be identified 
in the long history of cigarette abatement, and as noted in this 
piece, they are not foolproof and need to be continually assessed 
and amended to reflect changes in science and public response. 
However, in the face of e-cigarette triggered lung disease, 
warning labels take on a significant role in filling a regulatory 
void in the midst of a public health emergency. Unless these 
products are actually banned, it becomes critical to both 
strengthen e-cigarette warnings and expand the field of 
regulators and their responsibilities for crafting these new 
vaping warnings. E-cigarette and e-liquid warning labels should 
go beyond a brief statement about nicotine and also warn about 
the danger of inhaling chemical constituents of e-liquids that are 
carriers for the nicotine. The warnings should state that vaping 
products are dangerous and that it is recommended by medical 
authorities that individuals refrain from the recreational use of 
the product, as this practice may result in serious lung damage. 
Once e-cigarettes and e-liquids have undergone successful 
premarket review by the FDA, that should also be noted on the 
product label. In addition, like a food label, the chemical content 
in the e-cigarette ought to be disclosed, listed on the package, and 
jointly regulated by the CPSC.  
The arguments made by this new industry that e-cigarettes 
can lead to smoking cessation should not be casually dismissed 
 
 300 See Jim McDonald, An Obscure Safety Rule Could Shut Down the Vaping 
Industry, VAPING360 (Apr. 29, 2019), http://vaping360.com/vape-news/79053/an-obscure-
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also Letter from Mary F. Toro, Dir. of Regulatory Enf’t Div., Office of Compliance & Field 
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but need to be verified through extensive scientific research. The 
newest entry into the OTP market, the Philip Morris I Quit 
Ordinary Smoking (“IQOS”), is a heat-not-burn cigarette device 
that has obtained an FDA Premarket Tobacco Application 
(“PMTA”).301 The IQOS approval was granted based on the 
conclusion that this heat-not-burn product produces fewer or 
lower levels of toxins than traditional cigarettes.302 The FDA 
stresses that the award of the PMTA does not mean that the 
product is safe, and that the IQOS will be considered a cigarette, 
necessitating that they meet current labeling and advertising 
restrictions.303 The FDA decision is not without controversy, as 
health advocates have pointed out the lack of research, beyond 
Philip Morris’ own study, that the IQOS actually helps 
individuals either reduce smoking generally or that the product 
is any safer for an individual’s lungs and immune system.304 
VII. CONCLUSION 
In the annals of public health, few issues have garnered as 
much attention as cigarette smoking. Although dramatic 
progress has been made in smoking abatement, the emergence 
and rapid proliferation of other tobacco products, especially 
e-cigarettes, results in new challenges emerging in this arena. 
Package label warnings continue to be a foundational regulation 
needed to both educate and deter, dating back to the 1970s—the 
period in which the 91st Congress enacted the Public Health 
Cigarette Smoking Act. As smoking sparked multiple regulatory 
interventions, it is difficult to isolate the singular contribution of 
package warnings in isolation from other abatement measures. 
The review of the legislative history of tobacco label regulations 
leads to the conclusion that text-only warnings appear to have 
had diminishing returns on smoking prevention and cessation. 
While graphic warnings have garnered global support, there is 
simply no American experience with this approach and judging 
their impact prior to implementation, even in the face of more 
 
 301 See FDA permits sale of IQOS Tobacco Heating System through premarket tobacco 
product application pathway, FDA (Apr. 30, 2019), http://www.fda.gov/news-events/press-
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policy concerning PMTA in the context of IQOS, see Eric N. Lindblom, The Tobacco 
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CARE L. & POL’Y, (forthcoming 2020). 
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extensive research, is still a matter of speculation. On the other 
hand, it seems clear that current e-cigarette warnings need to be 
strengthened, and until the FDA engages in complete review of 
e-cigarette products, including e-liquids, multiple regulators 
should be encouraged to contribute to the development of more 
impactful product warnings.  
President Nixon’s reflection on cigarette warnings, a half 
century ago, which concluded that the government’s role is to 
simply provide information about risks and let individuals 
choose, belies the need for vigilance in addressing this ongoing 
public health challenge. Our society has paid, and continues to 
pay, a very high price in placating economic and alleged liberty 
interests related to tobacco.305 Both individual and population 
health demand maintenance of an aggressive posture in the 
smoking area, as this behavior has significant implications on 
the financial sustainability of the broader health system and the 
future of reforms in this sector. 
 
 
 
 
 305 See Gallagher v. City of Clayton, 699 F.3d 1013, 1017–18 (8th Cir. 2002). 
